Tyr185
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.9.2
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Tyr185  -  ERK2 (mouse)

Site Information
HtGFLtEyVAtRWYR   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 447594
Associated spectra:  1 CST

In vivo Characterization
Methods used to characterize site in vivo:
[32P] bio-synthetic labeling ( 443 , 464 , 552 , 565 , 567 , 568 , 570 ) , flow cytometry ( 166 , 324 ) , immunoprecipitation ( 6 , 9 , 14 , 39 , 44 , 132 , 139 , 197 , 209 , 220 , 557 ) , mass spectrometry ( 4 , 7 , 8 , 12 , 19 , 30 , 36 , 45 , 46 , 47 , 48 , 51 , 52 , 57 , 60 , 61 , 62 , 64 , 65 , 66 , 68 , 72 , 73 , 74 , 75 , 76 , 77 , 78 , 79 , 80 , 81 , 82 , 83 , 84 , 95 , 96 , 99 , 118 , 129 , 130 , 131 , 135 , 142 , 143 , 144 , 145 , 146 , 153 , 154 , 155 , 156 , 157 , 158 , 159 , 160 , 161 , 162 , 163 , 164 , 165 , 168 , 169 , 170 , 171 , 172 , 173 , 174 , 175 , 176 , 177 , 178 , 179 , 182 , 183 , 184 , 186 , 187 , 188 , 189 , 190 , 191 , 192 , 193 , 195 , 200 , 201 , 202 , 203 , 204 , 205 , 214 , 215 , 216 , 217 , 218 , 221 , 227 , 228 , 229 , 230 , 231 , 232 , 233 , 236 , 237 , 239 , 241 , 242 , 243 , 244 , 245 , 246 , 247 , 248 , 249 , 250 , 251 , 252 , 253 , 254 , 255 , 256 , 257 , 258 , 259 , 260 , 261 , 262 , 263 , 265 , 266 , 267 , 268 , 269 , 270 , 272 , 273 , 274 , 275 , 276 , 277 , 278 , 280 , 281 , 282 , 284 , 285 , 286 , 287 , 288 , 289 , 292 , 293 , 294 , 295 , 296 , 297 , 300 , 303 , 306 , 307 , 308 , 309 , 310 , 311 , 312 , 313 , 314 , 319 , 320 , 333 , 334 , 335 , 336 , 337 , 338 , 339 , 341 , 342 , 344 , 345 , 348 , 350 , 351 , 352 , 353 , 354 , 355 , 361 , 367 , 368 , 371 , 372 , 378 , 380 , 381 , 394 , 399 , 400 , 401 , 402 , 403 , 405 , 406 , 407 , 408 , 409 , 412 , 413 , 414 , 415 , 416 , 424 , 425 , 426 , 428 , 429 , 430 , 434 , 435 , 436 , 437 , 439 , 440 , 448 , 449 , 450 , 452 , 453 , 454 , 455 , 456 , 457 , 458 , 459 , 462 , 463 , 468 , 469 , 471 , 472 , 473 , 477 , 478 , 481 , 482 , 483 , 486 , 487 , 488 , 489 , 490 , 491 , 492 , 493 , 498 , 500 , 505 , 506 , 508 , 567 , 570 ) , mass spectrometry (in vitro) ( 134 ) , microscopy-colocalization with upstream kinase ( 530 ) , mutation of modification site ( 6 , 9 , 14 , 220 , 223 , 290 , 299 , 386 , 387 , 390 , 443 , 446 , 447 , 464 , 563 , 565 ) , phospho-antibody ( 1 , 2 , 3 , 6 , 9 , 10 , 11 , 13 , 14 , 15 , 16 , 17 , 18 , 21 , 23 , 24 , 25 , 26 , 27 , 28 , 29 , 31 , 32 , 33 , 34 , 35 , 38 , 39 , 40 , 41 , 43 , 44 , 49 , 54 , 55 , 56 , 58 , 67 , 68 , 69 , 71 , 85 , 86 , 89 , 91 , 93 , 94 , 97 , 98 , 102 , 103 , 104 , 105 , 106 , 107 , 108 , 109 , 110 , 111 , 112 , 113 , 114 , 115 , 116 , 117 , 119 , 120 , 122 , 123 , 124 , 125 , 126 , 127 , 128 , 132 , 133 , 136 , 137 , 138 , 139 , 140 , 141 , 147 , 148 , 149 , 150 , 151 , 152 , 166 , 167 , 176 , 180 , 181 , 185 , 194 , 196 , 197 , 198 , 199 , 207 , 208 , 209 , 210 , 211 , 212 , 213 , 219 , 220 , 222 , 223 , 224 , 225 , 226 , 234 , 235 , 238 , 240 , 271 , 283 , 290 , 291 , 298 , 299 , 301 , 304 , 305 , 316 , 318 , 321 , 322 , 323 , 324 , 325 , 326 , 327 , 328 , 329 , 330 , 331 , 332 , 340 , 343 , 346 , 347 , 349 , 356 , 357 , 358 , 359 , 360 , 362 , 363 , 364 , 365 , 366 , 369 , 370 , 373 , 374 , 375 , 376 , 377 , 379 , 382 , 383 , 384 , 385 , 386 , 387 , 388 , 389 , 390 , 391 , 392 , 393 , 395 , 396 , 397 , 398 , 404 , 419 , 420 , 421 , 423 , 427 , 431 , 432 , 433 , 438 , 441 , 442 , 443 , 444 , 445 , 446 , 447 , 451 , 460 , 461 , 465 , 466 , 467 , 470 , 474 , 475 , 476 , 479 , 480 , 484 , 485 , 494 , 495 , 496 , 498 , 499 , 501 , 502 , 503 , 504 , 509 , 510 , 511 , 512 , 513 , 514 , 515 , 516 , 517 , 518 , 519 , 521 , 522 , 523 , 524 , 525 , 526 , 527 , 528 , 529 , 530 , 531 , 532 , 533 , 534 , 535 , 536 , 537 , 538 , 539 , 541 , 542 , 543 , 544 , 545 , 546 , 547 , 548 , 549 , 550 , 551 , 552 , 553 , 554 , 555 , 557 , 558 , 559 , 560 , 561 , 562 , 563 , 564 , 565 ) , phosphopeptide mapping ( 552 , 568 , 570 ) , western blotting ( 1 , 2 , 3 , 6 , 9 , 10 , 11 , 13 , 14 , 15 , 16 , 17 , 18 , 21 , 23 , 24 , 25 , 26 , 27 , 28 , 29 , 31 , 32 , 33 , 34 , 35 , 38 , 39 , 40 , 41 , 43 , 44 , 49 , 54 , 55 , 56 , 58 , 67 , 68 , 69 , 71 , 85 , 86 , 88 , 89 , 91 , 93 , 94 , 97 , 98 , 102 , 103 , 104 , 105 , 106 , 107 , 108 , 109 , 110 , 111 , 112 , 113 , 114 , 115 , 116 , 117 , 119 , 120 , 121 , 122 , 123 , 124 , 125 , 126 , 127 , 128 , 132 , 133 , 136 , 137 , 138 , 139 , 140 , 141 , 147 , 148 , 149 , 150 , 151 , 152 , 166 , 167 , 180 , 181 , 185 , 194 , 196 , 197 , 198 , 199 , 207 , 208 , 209 , 210 , 211 , 212 , 213 , 219 , 220 , 222 , 223 , 224 , 225 , 226 , 234 , 235 , 238 , 240 , 271 , 283 , 290 , 291 , 298 , 299 , 301 , 304 , 316 , 318 , 321 , 322 , 323 , 325 , 326 , 327 , 328 , 329 , 330 , 331 , 332 , 340 , 343 , 346 , 347 , 349 , 356 , 357 , 359 , 362 , 363 , 364 , 365 , 366 , 369 , 370 , 373 , 374 , 375 , 376 , 377 , 379 , 382 , 383 , 384 , 385 , 386 , 387 , 388 , 389 , 390 , 391 , 392 , 395 , 396 , 397 , 398 , 419 , 423 , 431 , 432 , 438 , 446 , 461 , 465 , 466 , 467 , 470 , 474 , 475 , 479 , 480 , 484 , 485 , 495 , 496 , 499 , 501 , 502 , 504 , 509 , 511 , 512 , 513 , 514 , 515 , 516 , 518 , 519 , 521 , 522 , 525 , 526 , 527 , 529 , 532 , 535 , 536 , 541 , 542 , 543 , 548 , 549 , 550 , 551 , 552 , 553 , 554 , 557 , 558 , 559 , 562 , 563 , 564 )
Disease tissue studied:
adrenal cancer ( 518 ) , pheochromocytoma ( 518 ) , breast cancer ( 3 , 132 , 374 , 386 , 551 ) , cervical cancer ( 522 ) , cervical adenocarcinoma ( 522 ) , colorectal cancer ( 485 ) , colorectal carcinoma ( 485 ) , leukemia ( 60 , 190 , 191 , 192 , 193 , 291 , 307 , 308 , 309 , 310 , 311 , 312 , 313 , 314 , 486 , 487 , 488 , 489 , 490 , 543 ) , acute myelogenous leukemia ( 60 ) , acute erythroid leukemias, including erythroleukemia (M6a) and very rare pure erythroid leukemia (M6b) ( 291 , 543 ) , chronic myelogenous leukemia ( 307 , 308 , 309 , 310 , 311 , 312 , 313 , 314 , 486 , 487 , 488 , 489 , 490 ) , liver cancer ( 121 , 390 ) , lung cancer ( 111 , 278 , 280 , 281 , 282 , 284 , 285 , 286 , 292 , 293 , 294 , 295 , 296 , 297 , 349 , 377 , 466 ) , mesothelioma ( 466 ) , non-small cell lung cancer ( 111 , 129 , 278 , 280 , 281 , 282 , 292 , 293 , 294 , 295 , 296 , 297 ) , lymphoma ( 471 , 528 ) , B cell lymphoma ( 528 ) , neuroblastoma ( 99 , 105 , 480 , 504 , 521 ) , pancreatic cancer ( 132 , 149 , 301 ) , pancreatic carcinoma ( 132 , 149 , 301 ) , prostate cancer ( 68 ) , melanoma skin cancer ( 67 , 88 , 214 , 220 ) , testicular cancer ( 143 , 145 , 495 ) , diabetes mellitus ( 222 , 390 ) , type 2 diabetes ( 222 , 390 ) , Huntington's disease ( 39 ) , Turner-like syndrome ( 217 , 218 )
Relevant cell line - cell type - tissue:
'3T3-L1, differentiated' (adipocyte) ( 7 , 19 , 33 , 47 ) , 'B lymphocyte, precursor' ( 290 ) , 'brain, cerebellum' ( 52 , 438 , 549 ) , 'brain, cerebral cortex' ( 6 , 375 , 431 , 476 , 544 ) , 'brain, cerebrum' ( 438 , 549 ) , 'brain, embryonic' ( 288 , 350 , 352 ) , 'brain, embryonic' [BAG1 (mouse)] ( 422 ) , 'brain, hippocampus' ( 41 , 147 , 210 , 357 , 391 , 503 ) , 'brain, hippocampus' [DLG3 (mouse), homozygous knockout] ( 356 ) , 'brain, hypothalamus, suprachiasmatic nucleus' ( 445 ) , 'brain, striatum' ( 39 , 225 , 362 , 433 , 465 , 479 , 496 , 538 ) , 'epithelial, lung' [homozygous knockout] ( 120 ) , 'fat, brown' ( 118 ) , 'liver, fetal' ( 389 ) , 'muscle, skeletal' ( 196 , 283 ) , 'neuron, cortical'-brain ( 40 , 56 , 139 , 523 ) , 'neuron, cortical'-brain [NYAP2 (mouse), homozygous knockout] ( 71 ) , 'neuron, dorsal horn'-spinal cord ( 305 ) , 'neuron, hippocampal'-brain [neurogranin (mouse)] ( 535 ) , 'neuron, superior cervical ganglion' ( 235 ) , 'renal, podocyte' ( 127 ) , 'stem, embryonic' ( 153 , 154 , 155 , 156 , 157 , 158 , 159 , 160 , 161 , 162 , 163 , 164 , 165 , 168 , 169 , 170 , 171 , 172 , 173 , 174 , 175 , 283 ) , 'stem, mesenchymal' ( 319 , 320 ) , 21T (breast cell) ( 132 ) , 293 (epithelial) [DOR-1 (mouse)] ( 555 ) , 293 (epithelial) ( 34 , 212 , 446 , 447 , 552 ) , 32D (myeloid) ( 109 , 515 , 558 ) , 32Dcl3 (myeloid) [FLT3 (mouse), transfection, chimera with human FLT3-ITD mutant (corresponding to wild type P36888 ( 176 ) , 3T3 (fibroblast) [CDC42 (human), transfection] ( 45 ) , 3T3 (fibroblast) [INSR (human)] ( 552 ) , 3T3 (fibroblast) [INSR (mouse), transfection] ( 209 ) , 3T3 (fibroblast) [KRas (human), transfection] ( 45 ) , 3T3 (fibroblast) [Pyk2 (human), transfection, stable Pyk2 (v5-His tagged) transfection, in RU-486 (mifepristone)-inducible expression system] ( 135 ) , 3T3 (fibroblast) [SHP-2 (mouse), homozygous knockout] ( 404 , 420 , 444 , 446 , 464 , 466 , 467 , 513 , 517 , 534 , 560 , 563 , 564 ) , 3T3 (fibroblast) [Src (human)] ( 377 ) , 3T3 (fibroblast) ( 2 , 45 , 112 , 197 , 209 , 318 , 382 , 387 , 432 , 455 , 456 , 457 , 458 , 459 , 484 , 500 , 505 , 506 , 508 , 522 , 526 , 542 , 559 , 562 ) , 3T3-L1 (fibroblast) ( 55 , 93 , 148 , 328 , 330 , 340 , 394 , 509 ) , 4T1 (breast cell) ( 386 , 551 ) , 831/13 ( 491 , 492 , 493 ) , AB.1 (T lymphocyte) ( 124 ) , adipocyte-adipose tissue ( 548 ) , adipose tissue ( 283 ) , adipose tissue [DUSP6 (mouse), homozygous knockout] ( 35 ) , alphaT3-1 (pituitary cell) ( 43 ) , aorta ( 359 ) , artery ( 298 ) , B lymphocyte ( 77 , 78 , 290 ) , B lymphocyte-spleen ( 138 , 365 ) , B lymphocyte-spleen [PTEN (mouse), transgenic] ( 167 ) , B16 (melanocyte) ( 67 ) , B16F1 (melanocyte) ( 88 , 220 ) , B16F10 ( 11 ) , BAC1.2F5 (macrophage) ( 537 ) , BaF3 ('B lymphocyte, precursor') [EGFR (human)] ( 377 ) , BaF3 ('B lymphocyte, precursor') [FLT3 (human)] ( 392 ) , BaF3 ('B lymphocyte, precursor') ( 49 , 136 , 150 , 189 , 209 , 219 , 291 , 307 , 308 , 309 , 310 , 311 , 312 , 313 , 314 , 329 , 370 , 405 , 406 , 407 , 408 , 409 , 412 , 413 , 414 , 415 , 416 , 423 , 424 , 425 , 426 , 427 , 428 , 429 , 430 , 434 , 435 , 436 , 437 , 439 , 440 , 448 , 449 , 450 , 452 , 468 , 469 , 472 , 473 , 477 , 478 , 486 , 487 , 488 , 489 , 490 , 515 , 527 ) , BALB/MK (keratinocyte) ( 557 ) , beta-pancreas ( 149 ) , beta-pancreas [INSR (mouse), transgenic] ( 128 ) , bladder ( 304 ) , blood ( 60 ) , BMMC (mast) ( 38 , 116 , 553 ) , bone marrow ( 10 , 370 ) , brain ( 61 , 64 , 65 , 118 , 131 , 186 , 187 , 188 , 287 , 303 , 348 , 351 , 353 , 530 ) , brain [DARPP-32 (mouse), homozygous knockout] ( 470 ) , brain [NYAP2 (mouse), homozygous knockout] ( 71 ) , C2C12 (myoblast) ( 13 , 236 , 237 , 241 , 242 , 243 , 244 , 245 , 246 , 247 , 248 , 461 , 511 ) , C2C12-D (muscle cell) ( 354 , 355 ) , C3H10T1/2 (fibroblast) ( 265 , 266 , 267 , 268 , 369 ) , CCE ( 475 ) , CHO (fibroblast) ( 9 ) , CMT-93 (intestinal) ( 485 ) , colon ( 123 ) , COS (fibroblast) ( 18 , 49 , 209 , 384 , 484 , 524 , 525 ) , Dede (fibroblast) ( 565 ) , dendritic cell ( 1 , 318 ) , dendritic cell [MAPKAPK2 (mouse), homozygous knockout] ( 318 ) , dendritic cell [MSK1 (mouse), homozygous knockout] ( 318 ) , E14 ('neuron, hippocampal') ( 58 ) , E14tg2a ('stem, embryonic') ( 15 , 475 ) , EL-4 (T lymphocyte) ( 568 , 570 ) , embryo ( 65 , 389 ) , endothelial ( 226 ) , endothelial-pulmonary artery ( 133 ) , endothelial-vein ( 133 ) , epithelial-'kidney, tubule' ( 323 ) , epithelial-lens ( 343 ) , erythroblast ( 291 ) , ES (stem) ( 34 , 396 , 398 ) , F9 (testicular) ( 143 , 495 ) , Fao (hepatic) ( 121 , 390 ) , fibroblast-embryo [BAG1 (mouse)] ( 422 ) , fibroblast-lung ( 195 ) , GL261 (glial) ( 151 ) , GT1-7 (neuron) ( 321 , 393 ) , HaCaT (keratinocyte) ( 322 ) , heart ( 48 , 118 , 212 , 215 , 216 , 217 , 218 , 250 , 251 , 252 , 283 , 325 , 342 , 344 , 373 ) , HEK293T (epithelial) ( 9 , 56 , 89 , 132 , 563 ) , HEL (erythroid) ( 291 ) , HeLa (cervical) ( 108 , 464 ) , HeLa S3 (cervical) ( 522 ) , Hepa 1-6 (epithelial) ( 221 ) , hepatocyte ( 398 ) , HepG2 (hepatic) ( 390 ) , HT-22 (neuron) ( 523 ) , HT-4 (neuron) ( 523 ) , HUVEC (endothelial) ( 107 , 140 , 226 ) , IBE (endothelial) ( 529 ) , J2E (erythroblast) ( 543 ) , J774 (macrophage) ( 514 , 532 ) , JB (epithelial) ( 546 ) , JB6 RT101 (epidermal) ( 397 ) , Jurkat (T lymphocyte) ( 223 ) , keratinocyte ( 85 ) , kidney ( 118 ) , liver ( 4 , 46 , 57 , 65 , 118 , 121 , 208 , 283 , 289 , 337 , 338 , 339 , 341 , 345 , 361 , 390 , 481 , 482 , 483 , 539 ) , liver [Akt2 (mouse), homozygous knockout] ( 333 , 334 , 335 , 336 ) , LLC-PK1 (renal) ( 502 ) , lung ( 118 , 129 , 226 , 239 , 278 , 280 , 281 , 282 , 349 , 367 , 368 ) , lung [EGFR (mouse), transgenic, mutant] ( 285 ) , lung [EGFR (mouse), transgenic] ( 284 ) , lung [HRas (mouse), transgenic] ( 286 ) , lung [p27Kip1 (mouse), genetic knockin] ( 94 ) , macrophage ( 384 ) , macrophage-blood ( 447 ) , macrophage-bone marrow ( 21 , 54 , 331 , 358 , 364 ) , macrophage-bone marrow [Cot (mouse)] ( 316 ) , macrophage-bone marrow [NFkB-p105 (human)] ( 316 ) , macrophage-peritoneum ( 14 , 104 , 554 ) , mast-bone marrow ( 17 , 125 , 211 , 306 , 365 , 385 , 519 ) , mast-bone marrow [PTPRA (mouse), homozygous knockout] ( 224 ) , mast-bone marrow [SHP-2 (mouse), homozygous knockout] ( 180 ) , MC/9 (mast) ( 515 ) , MC3T3-E1 (preosteoblast) ( 12 ) , MCP-5 (mast) ( 306 ) , MCT cells (epithelial) ( 222 ) , MDA-MB-231 (breast cell) ( 3 ) , MEDF [HRas (mouse), HRas V12, HDAC6 -/+] ( 200 , 201 ) , MEF (fibroblast) ( 14 , 51 , 69 , 88 , 89 , 96 , 108 , 119 , 185 , 202 , 205 , 233 , 249 , 271 , 299 , 322 , 326 , 332 , 346 , 371 , 372 , 373 , 379 , 380 , 381 , 384 , 386 , 387 , 388 , 474 , 512 , 546 , 547 , 550 ) , MEF (fibroblast) [HRas (mouse), HRas V12] ( 203 , 204 ) , MEF (fibroblast) [IGF1R (mouse)] ( 360 , 421 , 441 , 460 , 494 ) , MEF (fibroblast) [LKB1 (mouse)] ( 501 ) , MEF (fibroblast) [MSK1 (mouse), homozygous knockout, msk2] ( 541 ) , MEF (fibroblast) [p53 (mouse), homozygous knockout] ( 95 ) , MEF (fibroblast) [PDGFRA (mouse), genetic knockin] ( 207 ) , MEF (fibroblast) [PKR (mouse), homozygous knockout] ( 114 ) , MEF (fibroblast) [PTP1B (mouse), homozygous knockout] ( 233 ) , MEF (fibroblast) [RAF1 (mouse), homozygous knockout] ( 234 ) , MEF (fibroblast) [Raptor (mouse), knockdown] ( 51 ) , MEF (fibroblast) [RICTOR (mouse), knockdown] ( 51 ) , MEF (fibroblast) [TSC2 (mouse), homozygous knockout] ( 96 ) , Mel-Ab (melanocyte) ( 110 ) , MES (pulmonary) ( 466 ) , mesangial ( 510 ) , microglia ( 363 ) , microvessel endothelial-lung [GIT1 (mouse), homozygous knockout] ( 44 ) , mIMCD-3 (epithelial) ( 536 , 561 ) , MIN6 (pancreatic) ( 149 , 301 ) , MLB13MYC (prechondroblast) ( 36 ) , MLE (epithelial) ( 443 ) , mLEC (epithelial) ( 103 ) , MLO-Y4 (osteoblast) ( 16 ) , MLP-29 ( 181 ) , MMTV-PyMT (breast cell) [JNK2 (mouse), homozygous knockout] ( 106 ) , mpkCCD (renal) ( 142 ) , MS1 (endothelial) ( 461 ) , myeloid ( 364 ) , myeloid-bone marrow ( 291 ) , myocyte-heart ( 32 , 212 , 327 , 373 , 419 , 442 ) , N18 (neuron) ( 521 ) , N1E-115 (neuron) ( 99 , 504 ) , Neuro-2a (neuron) ( 105 ) , neuron-'brain, cerebral cortex' ( 102 ) , neuron:postsynaptic density-'brain, hippocampus, CA1 region' ( 8 ) , NMuMG (epithelial) ( 551 ) , NSCLC (pulmonary) ( 111 ) , osteoclast ( 364 ) , P19 (testicular) ( 145 ) , PANC-1 (pancreatic) ( 132 ) , pancreas ( 118 ) , PC-12 (chromaffin) [TrkA (rat), transfection] ( 66 ) , PC-12 (chromaffin) ( 66 , 451 , 518 ) , preadipocyte ( 300 ) , preosteoclast ( 395 ) , prostate ( 68 ) , PYS-2 (epithelial) ( 146 ) , R1 ('stem, embryonic') ( 521 ) , R22 ('muscle, smooth') ( 299 ) , RAW 264 (macrophage) ( 447 ) , RAW 264.7 (macrophage) ( 30 , 113 , 190 , 191 , 192 , 193 , 199 ) , REF52 (fibroblast) ( 525 ) , SCC16-5 (fibroblast) ( 545 ) , skin ( 117 ) , skin [Fyn (mouse), transgenic] ( 152 ) , skin [mGluR1 (mouse), transgenic, TG mutant mice] ( 214 ) , SN56 (neuron) ( 480 ) , Sor4 ( 453 , 462 ) , SorA ( 454 , 463 ) , spleen ( 118 , 184 ) , STC-1 (endocrine) ( 531 ) , stromal ( 98 ) , Swiss 3T3 (fibroblast) ( 194 , 499 ) , SYF (fibroblast) [Src (mouse), transfection] ( 62 ) , SYF (fibroblast) ( 126 , 299 , 387 ) , T lymphocyte ( 238 ) , T lymphocyte [FOXO1A (mouse), transgenic] ( 97 ) , T lymphocyte [PELI1 (mouse), homozygous knockout] ( 86 ) , T lymphocyte-blood ( 213 , 324 ) , T lymphocyte-lymph node ( 130 , 166 , 347 , 365 ) , T lymphocyte-lymph node [PRKD1 (mouse), genetic knockin] ( 122 ) , T lymphocyte-lymph node [PRKD2 (mouse), genetic knockin] ( 122 ) , T lymphocyte-spleen ( 115 , 376 ) , T lymphocyte-spleen [LAT (mouse), transgenic] ( 141 ) , T47D (breast cell) ( 374 ) , testis ( 118 , 177 , 179 , 183 ) , thymocyte ( 383 ) , thymocyte [CBL (mouse), homozygous knockout] ( 137 ) , thymus ( 178 , 182 ) , thyroid [BRAF (human), genetic knockin] ( 91 ) , uterus ( 23 ) , vascular smooth muscle cell ('muscle, smooth') ( 240 , 299 ) , VSMC-aorta ( 516 ) , WEHI-231 (B lymphocyte) ( 528 )

Upstream Regulation
Regulatory protein:
AIF1 (mouse) ( 25 ) , Akt1 (mouse) ( 553 ) , ALK (human) ( 136 ) , ARAF (human) ( 301 ) , ARAF (mouse) ( 301 ) , ARHGEF7 (mouse) ( 387 ) , ARRB1 (mouse) ( 149 ) , BAG1 (mouse) ( 422 ) , Bcl-10 (mouse) ( 365 ) , BCR-ABL1 (human) ( 377 ) , BRAF (human) ( 235 ) , BRAF (mouse) ( 494 ) , Brk (mouse) ( 126 ) , CAMK2D (human) ( 321 ) , CARD11 (mouse) ( 365 ) , CARD9 (mouse) ( 26 ) , CBL (mouse) ( 383 ) , Cbl-b (mouse) ( 383 ) , CD151 (mouse) ( 17 ) , CD44 (mouse) ( 384 ) , CD74 (mouse) ( 384 ) , CDC42 iso1 (mouse) ( 387 ) , CDK5R1 (mouse) ( 465 ) , Cot (human) ( 89 ) , Cot (mouse) ( 441 ) , dectin-1 (mouse) ( 26 ) , DLG3 (mouse) ( 356 ) , DOK3 (mouse) ( 54 ) , DRD1 (mouse) ( 470 ) , DUSP19 (mouse) ( 524 ) , DUSP3 (mouse) ( 524 ) , DUSP6 (mouse) ( 35 , 121 ) , EAR-2 (mouse) ( 238 ) , EGFR (mouse) ( 299 ) , eNOS (mouse) ( 327 ) , ERG (mouse) ( 68 ) , ERK2 (mouse) ( 55 , 397 ) , FADD (mouse) ( 31 ) , FAK iso2 (mouse) ( 474 , 550 ) , FAK iso9 (mouse) ( 386 ) , FCER1A (mouse) ( 306 ) , Fes (mouse) ( 211 , 537 ) , FGFR1 (human) ( 329 ) , FGFR2 (human) ( 464 ) , FLT3 (human) ( 427 ) , FLT3 (mouse) ( 176 ) , FMR1 (mouse) ( 6 , 391 ) , FOXO1A (mouse) ( 121 ) , FOXP1 (mouse) ( 97 ) , G-alpha i2 (human) ( 89 ) , G-beta 1 (mouse) ( 89 ) , GAB2 (mouse) ( 10 ) , GIPC1 (mouse) ( 133 ) , GIT1 (human) ( 44 ) , GLRX1 (mouse) ( 343 ) , GRB10 (human) ( 49 ) , GRB10 (mouse) ( 22 ) , HePTP (mouse) ( 213 ) , HRas (mouse) ( 69 , 111 , 552 ) , ICMT (mouse) ( 512 ) , IGF1R (mouse) ( 497 ) , IL17RD (mouse) ( 513 ) , IRS1 (mouse) ( 548 ) , ITGA9 (human) ( 370 ) , JAK2 (human) ( 291 , 527 ) , JNK2 (mouse) ( 21 , 69 , 106 ) , KRas (mouse) ( 45 , 68 , 379 , 557 ) , KSR (human) ( 119 ) , LAB (mouse) ( 376 ) , LAT (mouse) ( 141 ) , MAPKAPK2 (mouse) ( 318 ) , MAPKAPK3 (mouse) ( 318 ) , MEK1 (mouse) ( 103 , 525 ) , MEKK1 (mouse) ( 34 ) , mGluR5 (mouse) ( 305 ) , MIEN1 (human) ( 3 ) , MRas (human) ( 515 ) , MSK1 (human) ( 541 ) , MSK1 (mouse) ( 541 ) , MSK2 (mouse) ( 541 ) , MST1 (human) ( 132 ) , neurogranin (mouse) ( 535 ) , NPC1 (mouse) ( 438 , 549 ) , NPM1 (human) ( 136 ) , NYAP2 (mouse) ( 71 ) , PAG (rat) ( 271 ) , PAK1 (human) ( 525 ) , PDGFRA (mouse) ( 207 ) , PDK1 (mouse) ( 283 , 398 ) , PELI1 (mouse) ( 86 ) , PHLPP (human) ( 132 ) , PHLPP2 (human) ( 132 ) , PKCA (mouse) ( 226 ) , PKCT (mouse) ( 298 ) , PPP1CC (human) ( 240 ) , PRKD1 (mouse) ( 499 ) , PRMT5 (human) ( 88 ) , PRMT5 (mouse) ( 88 ) , PRMT5 (rat) ( 88 ) , PTEN (mouse) ( 27 ) , PTP1B (mouse) ( 133 ) , PTPRB (mouse) ( 133 ) , PTPRJ (mouse) ( 133 ) , PTPRM (mouse) ( 133 ) , RAB11A (mouse) ( 133 ) , Rab7 (mouse) ( 133 ) , RAC1 (mouse) ( 525 ) , RAF1 (human) ( 88 ) , RAF1 (mouse) ( 525 ) , RAIG1 (mouse) ( 120 ) , Ret (human) ( 235 , 382 ) , RHOC (mouse) ( 67 ) , ROCK1 (mouse) ( 196 ) , SGPL1 (mouse) ( 89 ) , SH3BP2 (mouse) ( 364 ) , SHC1 iso2 (human) ( 360 ) , SHP-2 (mouse) ( 180 , 534 ) , Src (human) ( 377 ) , Src (mouse) ( 62 , 67 ) , Syk (mouse) ( 290 ) , syndecan-4 (mouse) ( 226 ) , TAK1 (mouse) ( 373 ) , TBK1 (mouse) ( 379 ) , Tel (human) ( 527 ) , TSC2 (mouse) ( 128 , 388 ) , UCP2 (mouse) ( 358 ) , VEGFR3 (mouse) ( 103 ) , Vinculin (mouse) ( 495 ) , ZAP70 (mouse) ( 290 )
Putative in vivo kinases:
MEK1 (mouse) ( 561 , 568 )
Kinases, in vitro:
ERK2 (mouse) ( 565 , 567 ) , ERK2 (rat) ( 566 ) , Lck (mouse) ( 569 ) , MEK1 (human) ( 568 ) , MEK1 (mouse) ( 525 ) , MEK1 (rabbit) ( 565 , 566 ) , MEK1 (rat) ( 134 )
Putative upstream phosphatases:
PPP2CA (mouse) ( 537 )
Treatments:
15d-PGJ2 ( 485 ) , 17-beta-estradiol ( 23 ) , 1Na-PP1 ( 139 ) , 22-hydroxycholesterol ( 443 ) , 5'-methylthioadenosine ( 88 ) , 8-(3-chlorostyryl) caffeine ( 325 ) , 9d ( 210 ) , A23187 ( 554 ) , acadesine ( 501 ) , adriamycin ( 114 ) , AG1296 ( 427 ) , AG1478 ( 85 , 127 , 194 , 451 ) , AG490 ( 34 , 514 ) , AGEs ( 14 ) , Akt-I-1 ( 301 ) , Akt_activator_compound_11 ( 112 ) , Akt_inhibitor_VIII ( 209 ) , alloxazine ( 325 ) , alpha-lipoic_acid ( 105 ) , amino_acid_starvation ( 209 ) , amino_acids ( 209 ) , amphoterin ( 521 ) , angiopoietin-1 ( 461 ) , angiopoietin-2 ( 461 ) , anisomycin ( 318 , 541 , 554 ) , anti-CD3 ( 124 , 137 , 223 , 324 , 347 , 383 , 410 ) , anti-CD3/CD28 ( 97 , 115 , 137 , 376 ) , anti-CD4 ( 137 , 383 ) , anti-CD8 ( 383 ) , anti-Fas ( 234 ) , anti-IgB ( 290 ) , anti-IgE ( 180 ) , anti-IgM ( 138 , 167 ) , anti-ITGA4 ( 461 ) , anti-ITGA6 ( 461 ) , anti-ITGB3 ( 461 ) , antichymotrypsin ( 375 ) , antigenic stimulation ( 125 ) , antitrypsin ( 375 ) , aphidicolin ( 484 ) , apigenin ( 514 ) , apomorphine ( 433 ) , atorvastatin ( 325 ) , bacterial infection ( 1 , 123 ) , BAPTA-AM ( 529 , 531 , 542 ) , Bay61-3606 ( 125 ) , BDNF ( 56 , 139 , 562 ) , benzo(a)pyrene ( 349 ) , beta-amyloid_40 ( 480 ) , betaxolol ( 431 ) , BFD-22 ( 11 ) , BI-D1870 ( 14 , 166 , 318 ) , bicuculline ( 102 ) , BIRA766 ( 125 ) , BIRB-0796 ( 318 ) , bisindolylmaleimide ( 521 ) , black_tea_polyphenols ( 117 ) , bombesin ( 194 , 499 ) , bradykinin ( 24 ) , brefeldin_A ( 176 ) , BRL37344 ( 467 ) , caffeine ( 362 ) , calphostin_C ( 521 ) , calyculin_A ( 557 ) , cAMP_analog ( 517 , 529 ) , cell_adhesion ( 213 ) , cell_detachment ( 495 ) , CGP77675 ( 502 ) , CGS_21680 ( 362 ) , chelerythrine ( 521 ) , ciclopirox_olamine ( 103 ) , cocaine ( 465 , 470 ) , cold_water_stress ( 357 ) , colforsin ( 119 , 362 , 446 , 460 , 504 , 529 , 535 ) , compound_56 ( 194 ) , compound_6 ( 140 ) , ConA ( 208 ) , curcumin ( 113 ) , curdlan ( 26 ) , CXCL12 ( 317 , 528 ) , cyclic_stretch ( 127 ) , cycloheximide ( 198 ) , cytochalasin_D ( 502 ) , dactolisib ( 63 ) , DDA ( 213 ) , depolarization ( 479 ) , desmopressin ( 142 ) , DETA-NONOate ( 327 ) , dexamethasone ( 328 , 369 ) , DHPG ( 305 , 391 ) , differentiation ( 111 ) , DMNQ ( 240 ) , DNP ( 553 ) , DPCPX ( 325 ) , DPDPE ( 555 ) , dronabinol ( 40 ) , DTLET ( 555 ) , EDTA ( 461 ) , EGF ( 24 , 34 , 85 , 88 , 106 , 119 , 120 , 126 , 197 , 233 , 323 , 346 , 366 , 369 , 387 , 446 , 451 , 467 , 484 , 494 , 499 , 512 , 513 , 524 , 525 , 533 , 534 , 536 , 540 , 541 , 547 , 551 , 552 , 557 , 561 , 564 ) , EGTA ( 198 ) , Epo ( 150 , 291 , 418 , 543 ) , epoxomicin ( 181 ) , estradiol ( 480 , 544 ) , ethanol ( 530 , 539 ) , ether ( 357 ) , faslodex ( 374 , 480 ) , fedratinib ( 291 ) , FGF1 ( 2 , 88 , 140 , 523 ) , FGF2 ( 88 , 226 , 513 , 518 , 529 ) , fibronectin ( 446 , 525 , 563 ) , fingolimod ( 39 ) , fisetin ( 41 ) , FL ( 392 , 427 ) , fluid_shear_stress ( 16 ) , food deprivation ( 357 ) , G-CSF ( 370 ) , GDNF ( 235 ) , gefitinib ( 377 ) , gelatin ( 521 ) , GF109203X ( 89 , 194 , 529 ) , GH ( 404 ) , GLP-1 ( 149 ) , glucose ( 127 , 128 , 222 , 507 , 510 , 540 ) , GnRH ( 43 , 321 ) , Go_6976 ( 521 ) , guanosine ( 363 ) , GW4869 ( 33 ) , H-89 ( 119 , 149 , 213 , 374 , 446 , 504 , 521 ) , H2O2 ( 124 , 127 , 360 , 432 , 451 ) , haloperidol ( 431 ) , heparin sodium ( 395 ) , herstatin ( 533 ) , HGF ( 88 , 561 ) , honokiol ( 93 ) , hypertonic_buffer ( 420 ) , hypoxia ( 148 ) , IBMX ( 119 , 328 , 369 , 446 , 460 ) , ICI-118,551 ( 431 ) , IFN-alpha ( 185 ) , IFN-gamma ( 363 , 514 , 545 ) , IgE ( 553 ) , IGF-1 ( 32 , 411 , 466 , 467 , 497 , 507 , 540 , 557 , 558 ) , IGF-2 ( 411 ) , IL-18 ( 18 ) , IL-1b ( 441 ) , IL-3 ( 136 , 291 , 423 , 427 , 515 , 527 , 558 ) , IL-33 ( 30 ) , IL-4 ( 515 ) , IL-6 ( 359 ) , IL-9 ( 515 ) , imatinib ( 136 ) , insulin ( 13 , 47 , 55 , 93 , 121 , 128 , 196 , 209 , 222 , 264 , 283 , 298 , 300 , 328 , 330 , 393 , 394 , 411 , 444 , 467 , 498 , 509 , 542 , 548 , 552 ) , ionomycin ( 86 , 124 , 365 , 557 ) , ischemia/reperfusion ( 327 , 417 ) , isoproterenol ( 467 , 517 ) , iturelix ( 321 ) , JNK_inhibitor_I ( 359 ) , kainic_acid ( 503 ) , KGF ( 464 ) , KN-93 ( 321 ) , KT5823 ( 102 ) , L-744,832 ( 557 ) , L-NAME ( 102 ) , laminin-1 ( 521 ) , leptin ( 532 ) , leucine ( 88 ) , levamfetamine ( 431 , 470 ) , licochalcone_A ( 199 ) , licochalcone_B ( 199 ) , licochalcone_C ( 199 ) , licochalcone_D ( 199 ) , LIF ( 396 , 475 ) , LIF withdrawal ( 15 ) , light ( 20 , 445 ) , lonafarnib ( 31 ) , long-term_potentiation ( 147 ) , low_glucose ( 127 ) , LPA ( 85 , 99 , 467 , 494 , 547 ) , LPS ( 21 , 54 , 104 , 113 , 199 , 318 , 358 , 447 , 485 , 539 ) , LY294002 ( 13 , 166 , 209 , 223 , 389 , 418 , 466 , 475 , 523 , 529 , 552 ) , M-CSF ( 331 , 364 , 526 , 537 ) , methotrexate ( 512 ) , methyl-beta-cyclodextrin ( 369 ) , methylphenidate ( 431 ) , MG132 ( 181 ) , midazolam ( 419 ) , MIF ( 384 ) , miR-181a ( 347 ) , MK801 ( 102 , 431 , 470 ) , MMS ( 388 ) , MnTBAP ( 102 ) , morphine ( 555 ) , MPTP ( 496 ) , MRS-1523 ( 325 ) , MSH ( 88 ) , muramyl_dipeptide ( 98 ) , NAC ( 105 ) , nicotine ( 511 ) , nifedipine ( 149 ) , NMDA ( 356 ) , nocodazole ( 484 ) , nomifensine ( 496 ) , NP68 ( 166 ) , NSC697923 ( 34 ) , NTCU ( 349 ) , NVP-BKM120 ( 63 ) , ODQ ( 102 ) , OH-BBN ( 304 ) , okadaic_acid ( 377 , 554 ) , orantinib ( 382 ) , OVA ( 122 ) , PACAP ( 445 ) , palmitate ( 298 , 326 ) , Pam3CSK4 ( 318 ) , papaverine ( 225 ) , PAR1-activating_peptide ( 519 ) , PD0325901 ( 31 ) , PD169316 ( 546 ) , PD184352 ( 23 , 318 , 541 ) , PD90059 ( 374 ) , PD98059 ( 13 , 14 , 43 , 105 , 123 , 226 , 301 , 359 , 423 , 443 , 466 , 467 , 480 , 485 , 504 , 514 , 516 , 518 , 520 , 522 , 523 , 529 , 532 , 546 , 552 , 557 , 558 , 561 ) , PDGF ( 66 , 207 , 340 , 343 , 513 , 516 , 547 , 550 ) , peptones ( 531 ) , PGE2 ( 16 , 116 , 315 ) , phorbol_ester ( 86 , 88 , 117 , 198 , 318 , 365 , 404 , 494 , 502 , 529 , 535 , 541 , 547 , 554 , 557 , 568 , 570 ) , pilocarpine ( 503 ) , PKC-theta_pseudosubstrate ( 298 ) , PKC412 ( 176 ) , poly-L-lysine ( 563 ) , pomegranate_wine ( 349 ) , PP1 ( 43 , 552 ) , PP2 ( 223 , 369 , 384 , 497 , 529 , 544 ) , prazosin ( 431 ) , progestin_R5020 ( 374 ) , propranolol ( 431 ) , PTH(1-34) ( 12 ) , PTX ( 89 , 504 ) , racepinefrine ( 517 ) , Raf1_kinase_inhibitor_I ( 301 ) , RANKL ( 364 ) , rapamycin ( 23 , 28 , 32 , 116 , 128 , 166 , 209 , 398 , 466 , 520 , 557 ) , refeeding ( 46 ) , restraint stress ( 59 ) , resveratrol ( 117 ) , retinoic_acid ( 443 , 521 ) , RGD ( 461 ) , RGE ( 461 ) , rimonabant ( 504 ) , rolipram ( 225 ) , rosiglitazone ( 93 ) , rottlerin ( 360 ) , S107 ( 59 ) , SB202190 ( 366 , 546 , 554 , 557 ) , SB203580 ( 198 , 318 , 502 , 541 ) , SCF ( 219 , 224 , 385 , 519 ) , SCH_23390 ( 431 , 470 ) , seliciclib ( 479 ) , semaxanib ( 382 ) , serum ( 198 , 234 , 398 , 432 , 494 , 513 , 547 , 555 , 557 ) , serum_withdrawal ( 522 ) , silibinin ( 304 ) , silymarin ( 304 ) , siRNA ( 330 , 387 ) , SKF82958 ( 503 ) , SL0101 ( 318 ) , SL327 ( 433 ) , SMI11293 ( 139 ) , sorbitol ( 564 ) , SP600125 ( 497 ) , sphingomyelin ( 33 ) , sphingosine_1-phosphate ( 27 , 110 ) , SPT ( 325 ) , staurosporine ( 360 ) , streptozotocin ( 390 ) , SU5402 ( 389 ) , SU6656 ( 377 ) , sunitinib ( 382 ) , TAK1_inhibitor ( 34 ) , TCAP-1 ( 58 ) , TCDD ( 369 ) , TDZD-8 ( 151 ) , TGF-alpha ( 533 , 540 ) , TGF-beta ( 34 , 91 , 299 , 538 , 551 ) , Theophylline ( 325 ) , thrombin ( 89 , 419 , 519 ) , thrombospondin ( 474 ) , TNF ( 318 , 332 , 363 , 441 , 556 ) , Torin1 ( 116 ) , triciribine ( 105 ) , TTX ( 476 ) , TUG-891 ( 9 ) , tunicamycin ( 176 ) , U0126 ( 50 , 58 , 88 , 91 , 103 , 113 , 124 , 128 , 149 , 185 , 198 , 209 , 213 , 235 , 290 , 301 , 323 , 325 , 329 , 369 , 385 , 389 , 404 , 427 , 432 , 460 , 475 , 479 , 480 , 504 , 519 , 521 , 522 , 523 , 529 , 536 , 554 ) , urethane ( 94 ) , UV ( 397 , 520 , 541 , 546 ) , vasopressin ( 194 , 499 ) , VEGF ( 133 , 140 ) , visual experience ( 476 ) , vitronectin ( 461 ) , WIN ( 40 , 504 ) , wortmannin ( 105 , 116 , 128 , 149 , 166 , 329 , 466 , 529 , 557 ) , Y27632 ( 502 ) , YM-254890 ( 9 ) , yohimbine ( 431 ) , Zn(2+) ( 139 ) , zymosan ( 554 )

Downstream Regulation
Effects of modification on ERK2:
enzymatic activity, induced ( 69 , 210 , 420 , 427 , 443 , 533 , 560 , 561 , 565 , 566 , 568 ) , intracellular localization ( 88 )
Effects of modification on biological processes:
apoptosis, inhibited ( 117 ) , carcinogenesis, induced ( 117 ) , carcinogenesis, inhibited ( 69 ) , cell growth, inhibited ( 69 ) , neural plasticity ( 102 ) , signaling pathway regulation ( 88 ) , transcription, altered ( 554 ) , transcription, induced ( 24 )
Induce interaction with:
GAB1 (human) ( 561 )

Disease / Diagnostics Relevance
Relevant diseases:
cancer, squamous cell carcinoma ( 152 )

References 

1

Fabrik I, et al. (2018) The Early Dendritic Cell Signaling Induced by Virulent Francisella tularensis Strain Occurs in Phases and Involves the Activation of Extracellular Signal-Regulated Kinases (ERKs) and p38 In the Later Stage. Mol Cell Proteomics 17, 81-94
29046388   Curated Info

2

Huang Z, et al. (2017) Uncoupling the Mitogenic and Metabolic Functions of FGF1 by Tuning FGF1-FGF Receptor Dimer Stability. Cell Rep 20, 1717-1728
28813681   Curated Info

3

Wang Y, et al. (2017) Inhibition of MAPK pathway is essential for suppressing Rheb-Y35N driven tumor growth. Oncogene 36, 756-765
27399332   Curated Info

4

Robles MS, Humphrey SJ, Mann M (2017) Phosphorylation Is a Central Mechanism for Circadian Control of Metabolism and Physiology. Cell Metab 25, 118-127
27818261   Curated Info

5

Sacco F, et al. (2016) Glucose-regulated and drug-perturbed phosphoproteome reveals molecular mechanisms controlling insulin secretion. Nat Commun 7, 13250
27841257   Curated Info

6

Sawicka K, et al. (2016) Elevated ERK/p90 ribosomal S6 kinase activity underlies audiogenic seizure susceptibility in fragile X mice. Proc Natl Acad Sci U S A 113, E6290-E6297
27663742   Curated Info

7

Minard AY, et al. (2016) mTORC1 Is a Major Regulatory Node in the FGF21 Signaling Network in Adipocytes. Cell Rep 17, 29-36
27681418   Curated Info

8

Li J, et al. (2016) Long-term potentiation modulates synaptic phosphorylation networks and reshapes the structure of the postsynaptic interactome. Sci Signal 9, rs8
27507650   Curated Info

9

Prihandoko R, et al. (2016) Distinct Phosphorylation Clusters Determine the Signaling Outcome of Free Fatty Acid Receptor 4/G Protein-Coupled Receptor 120. Mol Pharmacol 89, 505-20
26873857   Curated Info

10

Gu S, et al. (2016) Distinct GAB2 signaling pathways are essential for myeloid and lymphoid transformation and leukemogenesis by BCR-ABL1. Blood 127, 1803-13
26773044   Curated Info

11

Ferreira AK, et al. (2016) BFD-22 a new potential inhibitor of BRAF inhibits the metastasis of B16F10 melanoma cells and simultaneously increased the tumor immunogenicity. Toxicol Appl Pharmacol 295, 56-67
26876618   Curated Info

12

Williams GR, et al. (2016) Exploring G protein-coupled receptor signaling networks using SILAC-based phosphoproteomics. Methods 92, 36-50
26160508   Curated Info

13

Litwiniuk A, et al. (2016) FOXO1 and GSK-3β Are Main Targets of Insulin-Mediated Myogenesis in C2C12 Muscle Cells. PLoS One 11, e0146726
26785133   Curated Info

14

Peng Y, et al. (2016) AGE-RAGE signal generates a specific NF-κB RelA "barcode" that directs collagen I expression. Sci Rep 6, 18822
26729520   Curated Info

15

Cherepkova MY, Sineva GS, Pospelov VA (2016) Leukemia inhibitory factor (LIF) withdrawal activates mTOR signaling pathway in mouse embryonic stem cells through the MEK/ERK/TSC2 pathway. Cell Death Dis 7, e2050
26775702   Curated Info

16

Riquelme MA, et al. (2015) Mitogen-activated Protein Kinase (MAPK) Activated by Prostaglandin E2 Phosphorylates Connexin 43 and Closes Osteocytic Hemichannels in Response to Continuous Flow Shear Stress. J Biol Chem 290, 28321-8
26442583   Curated Info

17

Abdala-Valencia H, et al. (2015) Tetraspanin CD151 Is a Negative Regulator of FcεRI-Mediated Mast Cell Activation. J Immunol 195, 1377-87
26136426   Curated Info

18

Wang J, et al. (2015) Interleukin 18 function in atherosclerosis is mediated by the interleukin 18 receptor and the Na-Cl co-transporter. Nat Med 21, 820-6
26099046   Curated Info

19

Parker BL, et al. (2015) Targeted phosphoproteomics of insulin signaling using data-independent acquisition mass spectrometry. Sci Signal 8, rs6
26060331   Curated Info

20

Cao R, et al. (2015) Light-regulated translational control of circadian behavior by eIF4E phosphorylation. Nat Neurosci 18, 855-62
25915475   Curated Info

21

Zhang Q, et al. (2015) The kinase Jnk2 promotes stress-induced mitophagy by targeting the small mitochondrial form of the tumor suppressor ARF for degradation. Nat Immunol 16, 458-66
25799126   Curated Info

22

Mroue R, et al. (2015) Monoallelic loss of the imprinted gene grb10 promotes tumor formation in irradiated nf1+/- mice. PLoS Genet 11, e1005235
26000738   Curated Info

23

Wang Y, Zhu L, Kuokkanen S, Pollard JW (2015) Activation of protein synthesis in mouse uterine epithelial cells by estradiol-17β is mediated by a PKC-ERK1/2-mTOR signaling pathway. Proc Natl Acad Sci U S A 112, E1382-91
25733860   Curated Info

24

Breit A, et al. (2015) Serine-727 Phosphorylation Activates Hypothalamic STAT-3 Independently From Tyrosine-705 Phosphorylation. Mol Endocrinol 29, 445-59
25584415   Curated Info

25

Tuominen I, et al. (2015) AIP inactivation leads to pituitary tumorigenesis through defective Gαi-cAMP signaling. Oncogene 34, 1174-84
24662816   Curated Info

26

Baldwin KT, Carbajal KS, Segal BM, Giger RJ (2015) Neuroinflammation triggered by β-glucan/dectin-1 signaling enables CNS axon regeneration. Proc Natl Acad Sci U S A 112, 2581-6
25675510   Curated Info

27

Leong JW, et al. (2015) PTEN regulates natural killer cell trafficking in vivo. Proc Natl Acad Sci U S A 112, E700-9
25646418   Curated Info

28

Akeno N, Miller AL, Ma X, Wikenheiser-Brokamp KA (2015) p53 suppresses carcinoma progression by inhibiting mTOR pathway activation. Oncogene 34, 589-99
24469052   Curated Info

29

Damsky W, et al. (2015) mTORC1 activation blocks BrafV600E-induced growth arrest but is insufficient for melanoma formation. Cancer Cell 27, 41-56
25584893   Curated Info

30

Pinto SM, et al. (2015) Quantitative phosphoproteomic analysis of IL-33-mediated signaling. Proteomics 15, 532-44
25367039   Curated Info

31

Bowman BM, et al. (2015) Phosphorylation of FADD by the kinase CK1α promotes KRASG12D-induced lung cancer. Sci Signal 8, ra9
25628462   Curated Info

32

Kusch A, et al. (2015) 17ß-Estradiol regulates mTORC2 sensitivity to rapamycin in adaptive cardiac remodeling. PLoS One 10, e0123385
25880554   Curated Info

33

Makdissy N, et al. (2015) Regulation of SREBPs by Sphingomyelin in Adipocytes via a Caveolin and Ras-ERK-MAPK-CREB Signaling Pathway. PLoS One 10, e0133181
26230734   Curated Info

34

Charlaftis N, et al. (2014) The MEKK1 PHD ubiquitinates TAB1 to activate MAPKs in response to cytokines. EMBO J 33, 2581-96
25260751   Curated Info

35

Feng B, et al. (2014) Mitogen-Activated Protein Kinase Phosphatase 3 (MKP-3)-Deficient Mice Are Resistant to Diet-Induced Obesity. Diabetes 63, 2924-34
24722245   Curated Info

36

Bordoli MR, et al. (2014) A secreted tyrosine kinase acts in the extracellular environment. Cell 158, 1033-44
25171405   Curated Info

37

Mertins P, et al. (2014) Ischemia in tumors induces early and sustained phosphorylation changes in stress kinase pathways but does not affect global protein levels. Mol Cell Proteomics 13, 1690-704
24719451   Curated Info

38

Wu Z, et al. (2014) Calpain-1 contributes to IgE-mediated mast cell activation. J Immunol 192, 5130-9
24760147   Curated Info

39

Di Pardo A, et al. (2014) FTY720 (fingolimod) is a neuroprotective and disease-modifying agent in cellular and mouse models of Huntington disease. Hum Mol Genet 23, 2251-65
24301680   Curated Info

40

Tortoriello G, et al. (2014) Miswiring the brain: Δ9-tetrahydrocannabinol disrupts cortical development by inducing an SCG10/stathmin-2 degradation pathway. EMBO J 33, 668-85
24469251   Curated Info

41

Currais A, et al. (2014) Modulation of p25 and inflammatory pathways by fisetin maintains cognitive function in Alzheimer's disease transgenic mice. Aging Cell 13, 379-90
24341874   Curated Info

42

Lin A, et al. (2014) FoxO transcription factors promote AKT Ser473 phosphorylation and renal tumor growth in response to pharmacologic inhibition of the PI3K-AKT pathway. Cancer Res 74, 1682-93
24448243   Curated Info

43

Navratil AM, et al. (2014) Role of cortactin in dynamic actin remodeling events in gonadotrope cells. Endocrinology 155, 548-57
24274984   Curated Info

44

Majumder S, et al. (2014) G-Protein-Coupled Receptor-2-Interacting Protein-1 Is Required for Endothelial Cell Directional Migration and Tumor Angiogenesis via Cortactin-Dependent Lamellipodia Formation. Arterioscler Thromb Vasc Biol 34, 419-26
24265417   Curated Info

45

Gnad F, et al. (2013) Systems-wide Analysis of K-Ras, Cdc42, and PAK4 Signaling by Quantitative Phosphoproteomics. Mol Cell Proteomics 12, 2070-80
23608596   Curated Info

46

Wilson-Grady JT, Haas W, Gygi SP (2013) Quantitative comparison of the fasted and re-fed mouse liver phosphoproteomes using lower pH reductive dimethylation. Methods 61, 277-86
23567750   Curated Info

47

Humphrey SJ, et al. (2013) Dynamic Adipocyte Phosphoproteome Reveals that Akt Directly Regulates mTORC2. Cell Metab 17, 1009-20
23684622   Curated Info

48

Lundby A, et al. (2013) In vivo phosphoproteomics analysis reveals the cardiac targets of β-adrenergic receptor signaling. Sci Signal 6, rs11
23737553   Curated Info

49

Kazi JU, Rönnstrand L (2013) FLT3 signals via the adapter protein Grb10 and overexpression of Grb10 leads to aberrant cell proliferation in acute myeloid leukemia. Mol Oncol 7, 402-18
23246379   Curated Info

50

Xie Y, et al. (2013) Stress induces AMP-dependent loss of potency factors Id2 and Cdx2 in early embryos and stem cells. Stem Cells Dev 22, 1564-75
23316940   Curated Info

51

Robitaille AM, et al. (2013) Quantitative phosphoproteomics reveal mTORC1 activates de novo pyrimidine synthesis. Science 339, 1320-3
23429704   Curated Info

52

Schindler J, Ye J, Jensen ON, Nothwang HG (2013) Monitoring the native phosphorylation state of plasma membrane proteins from a single mouse cerebellum. J Neurosci Methods 213, 153-64
23246975   Curated Info

53

Utreras E, et al. (2013) TGF-β1 sensitizes TRPV1 through Cdk5 signaling in odontoblast-like cells. Mol Pain 9, 24
23668392   Curated Info

54

Peng Q, Long CL, Malhotra S, Humphrey MB (2013) A Physical Interaction Between the Adaptor Proteins DOK3 and DAP12 Is Required to Inhibit Lipopolysaccharide Signaling in Macrophages. Sci Signal 6, ra72
23962980   Curated Info

55

Woody S, Stall R, Ramos J, Patel YM (2013) Regulation of myosin light chain kinase during insulin-stimulated glucose uptake in 3T3-L1 adipocytes. PLoS One 8, e77248
24116218   Curated Info

56

Lai KO, et al. (2012) TrkB phosphorylation by Cdk5 is required for activity-dependent structural plasticity and spatial memory. Nat Neurosci 15, 1506-15
23064382   Curated Info

57

Grimsrud PA, et al. (2012) A quantitative map of the liver mitochondrial phosphoproteome reveals posttranslational control of ketogenesis. Cell Metab 16, 672-83
23140645   Curated Info

58

Chand D, et al. (2012) C-Terminal region of teneurin-1 co-localizes with dystroglycan and modulates cytoskeletal organization through an extracellular signal-regulated kinase-dependent stathmin- and filamin A-mediated mechanism in hippocampal cells. Neuroscience 219, 255-70
22698694   Curated Info

59

Liu X, et al. (2012) Role of leaky neuronal ryanodine receptors in stress-induced cognitive dysfunction. Cell 150, 1055-67
22939628   Curated Info

60

Trost M, et al. (2012) Posttranslational regulation of self-renewal capacity: insights from proteome and phosphoproteome analyses of stem cell leukemia. Blood 120, e17-27
22802335   Curated Info

61

Trinidad JC, et al. (2012) Global identification and characterization of both O-GlcNAcylation and phosphorylation at the murine synapse. Mol Cell Proteomics 11, 215-29
22645316   Curated Info

62

Ferrando IM, et al. (2012) Identification of targets of c-Src tyrosine kinase by chemical complementation and phosphoproteomics. Mol Cell Proteomics 11, 355-69
22499769   Curated Info

63

Gallagher EJ, et al. (2012) Inhibiting PI3K reduces mammary tumor growth and induces hyperglycemia in a mouse model of insulin resistance and hyperinsulinemia. Oncogene 31, 3213-22
22037215   Curated Info

64

Goswami T, et al. (2012) Comparative phosphoproteomic analysis of neonatal and adult murine brain. Proteomics 12, 2185-9
22807455   Curated Info

65

Stokes MP, et al. (2012) PTMScan Direct: Identification and Quantification of Peptides from Critical Signaling Proteins by Immunoaffinity Enrichment Coupled with LC-MS/MS. Mol Cell Proteomics 11, 187-201
22322096   Curated Info

66

Biarc J, Chalkley RJ, Burlingame AL, Bradshaw RA (2012) The induction of serine/threonine protein phosphorylations by a PDGFR/TrkA chimera in stably transfected PC12 cells. Mol Cell Proteomics 11, 15-30
22027198   Curated Info

67

Arpaia E, et al. (2012) The interaction between caveolin-1 and Rho-GTPases promotes metastasis by controlling the expression of alpha5-integrin and the activation of Src, Ras and Erk. Oncogene 31, 884-96
21765460   Curated Info

68

Drake JM, et al. (2012) Oncogene-specific activation of tyrosine kinase networks during prostate cancer progression. Proc Natl Acad Sci U S A 109, 1643-8
22307624   Curated Info

69

Mathiasen DP, et al. (2012) Identification of a c-Jun N-terminal kinase-2-dependent signal amplification cascade that regulates c-Myc levels in ras transformation. Oncogene 31, 390-401
21706057   Curated Info

70

Packer LM, et al. (2011) Nilotinib and MEK inhibitors induce synthetic lethality through paradoxical activation of RAF in drug-resistant chronic myeloid leukemia. Cancer Cell 20, 715-27
22169110   Curated Info

71

Yokoyama K, et al. (2011) NYAP: a phosphoprotein family that links PI3K to WAVE1 signalling in neurons. EMBO J 30, 4739-54
21946561   Curated Info

72

Ren H (2011) CST Curation Set: 12902; Year: 2011; Biosample/Treatment: /untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

73

Ren H (2011) CST Curation Set: 12903; Year: 2011; Biosample/Treatment: /untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

74

Ren H (2011) CST Curation Set: 12904; Year: 2011; Biosample/Treatment: /untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

75

Ren H (2011) CST Curation Set: 12905; Year: 2011; Biosample/Treatment: /untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

76

Ren H (2011) CST Curation Set: 12906; Year: 2011; Biosample/Treatment: /untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

77

Ren H (2011) CST Curation Set: 12893; Year: 2011; Biosample/Treatment: primary cells, B lymphocyte/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

78

Ren H (2011) CST Curation Set: 12894; Year: 2011; Biosample/Treatment: primary cells, B lymphocyte/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

79

Ren H (2011) CST Curation Set: 12895; Year: 2011; Biosample/Treatment: /untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

80

Ren H (2011) CST Curation Set: 12896; Year: 2011; Biosample/Treatment: /untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

81

Ren H (2011) CST Curation Set: 12897; Year: 2011; Biosample/Treatment: /untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

82

Ren H (2011) CST Curation Set: 12898; Year: 2011; Biosample/Treatment: /untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

83

Ren H (2011) CST Curation Set: 12900; Year: 2011; Biosample/Treatment: /untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

84

Ren H (2011) CST Curation Set: 12901; Year: 2011; Biosample/Treatment: /untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

85

Inoue A, et al. (2011) LPA-producing enzyme PA-PLA₁α regulates hair follicle development by modulating EGFR signalling. EMBO J 30, 4248-60
21857648   Curated Info

86

Chang M, et al. (2011) The ubiquitin ligase Peli1 negatively regulates T cell activation and prevents autoimmunity. Nat Immunol 12, 1002-9
21874024   Curated Info

87

Nohara A, et al. (2011) Cyclin-dependent kinase-5 is a key molecule in tumor necrosis factor-α-induced insulin resistance. J Biol Chem 286, 33457-65
21813649   Curated Info

88

Andreu-Pérez P, et al. (2011) Protein arginine methyltransferase 5 regulates ERK1/2 signal transduction amplitude and cell fate through CRAF. Sci Signal 4, ra58
21917714   Curated Info

89

Hatziapostolou M, et al. (2011) Tumor progression locus 2 mediates signal-induced increases in cytoplasmic calcium and cell migration. Sci Signal 4, ra55
21868363   Curated Info

90

Oneyama C, et al. (2011) MicroRNA-mediated downregulation of mTOR/FGFR3 controls tumor growth induced by Src-related oncogenic pathways. Oncogene 30, 3489-501
21383697   Curated Info

91

Knauf JA, et al. (2011) Progression of BRAF-induced thyroid cancer is associated with epithelial-mesenchymal transition requiring concomitant MAP kinase and TGFβ signaling. Oncogene 30, 3153-62
21383698   Curated Info

92

Ryu JM, Han HJ (2011) L-threonine regulates G1/S phase transition of mouse embryonic stem cells via PI3K/Akt, MAPKs, and mTORC pathways. J Biol Chem 286, 23667-78
21550972   Curated Info

93

Choi SS, et al. (2011) Honokiol enhances adipocyte differentiation by potentiating insulin signaling in 3T3-L1 preadipocytes. J Nat Med 65, 424-30
21327521   Curated Info

94

Serres MP, et al. (2011) Cytoplasmic p27 is oncogenic and cooperates with Ras both in vivo and in vitro. Oncogene 30, 2846-58
21317921   Curated Info

95

Hsu PP, et al. (2011) The mTOR-regulated phosphoproteome reveals a mechanism of mTORC1-mediated inhibition of growth factor signaling. Science 332, 1317-22
21659604   Curated Info

96

Yu Y, et al. (2011) Phosphoproteomic analysis identifies Grb10 as an mTORC1 substrate that negatively regulates insulin signaling. Science 332, 1322-6
21659605   Curated Info

97

Feng X, et al. (2011) Transcription factor Foxp1 exerts essential cell-intrinsic regulation of the quiescence of naive T cells. Nat Immunol 12, 544-50
21532575   Curated Info

98

Kim YG, et al. (2011) The Nod2 sensor promotes intestinal pathogen eradication via the chemokine CCL2-dependent recruitment of inflammatory monocytes. Immunity 34, 769-80
21565531   Curated Info

99

Wang Y, et al. (2011) Spatial phosphoprotein profiling reveals a compartmentalized extracellular signal-regulated kinase switch governing neurite growth and retraction. J Biol Chem 286, 18190-201
21454597   Curated Info

100

Bard-Chapeau EA, et al. (2011) Ptpn11/Shp2 acts as a tumor suppressor in hepatocellular carcinogenesis. Cancer Cell 19, 629-39
21575863   Curated Info

101

Patterson SJ, et al. (2011) Cutting edge: PHLPP regulates the development, function, and molecular signaling pathways of regulatory T cells. J Immunol 186, 5533-7
21498666   Curated Info

102

Gallo EF, Iadecola C (2011) Neuronal nitric oxide contributes to neuroplasticity-associated protein expression through cGMP, protein kinase G, and extracellular signal-regulated kinase. J Neurosci 31, 6947-55
21562256   Curated Info

103

Luo Y, et al. (2011) The fungicide ciclopirox inhibits lymphatic endothelial cell tube formation by suppressing VEGFR-3-mediated ERK signaling pathway. Oncogene 30, 2098-107
21217783   Curated Info

104

Liu X, et al. (2011) Intracellular MHC class II molecules promote TLR-triggered innate immune responses by maintaining activation of the kinase Btk. Nat Immunol 12, 416-24
21441935   Curated Info

105

Wang X, et al. (2011) Essential role of ERK activation in neurite outgrowth induced by α-lipoic acid. Biochim Biophys Acta 1813, 827-38
21295083   Curated Info

106

Mitra S, Lee JS, Cantrell M, Van den Berg CL (2011) c-Jun N-terminal kinase 2 (JNK2) enhances cell migration through epidermal growth factor substrate 8 (EPS8). J Biol Chem 286, 15287-97
21357683   Curated Info

107

Xu K, et al. (2011) Blood vessel tubulogenesis requires Rasip1 regulation of GTPase signaling. Dev Cell 20, 526-39
21396893   Curated Info

108

Saci A, Cantley LC, Carpenter CL (2011) Rac1 regulates the activity of mTORC1 and mTORC2 and controls cellular size. Mol Cell 42, 50-61
21474067   Curated Info

109

Arora D, et al. (2011) Protein-tyrosine phosphatase DEP-1 controls receptor tyrosine kinase FLT3 signaling. J Biol Chem 286, 10918-29
21262971   Curated Info

110

Kim DS, et al. (2011) Sphingosine-1-phosphate decreases melanin synthesis via microphthalmia-associated transcription factor phosphorylation through the S1P3 receptor subtype. J Pharm Pharmacol 63, 409-16
21749389   Curated Info

111

Calbo J, et al. (2011) A functional role for tumor cell heterogeneity in a mouse model of small cell lung cancer. Cancer Cell 19, 244-56
21316603   Curated Info

112

Georgiades SN, et al. (2011) Identification of a potent activator of Akt phosphorylation from a novel series of phenolic, picolinic, pyridino, and hydroxamic zinc(II) complexes. J Biol Inorg Chem 16, 195-208
20972690   Curated Info

113

Ben P, et al. (2011) Curcumin promotes degradation of inducible nitric oxide synthase and suppresses its enzyme activity in RAW 264.7 cells. Int Immunopharmacol 11, 179-86
21094287   Curated Info

114

Peidis P, et al. (2011) Doxorubicin bypasses the cytoprotective effects of eIF2α phosphorylation and promotes PKR-mediated cell death. Cell Death Differ 18, 145-54
20559319   Curated Info

115

Driessens G, et al. (2011) Beta-catenin inhibits T cell activation by selective interference with linker for activation of T cells-phospholipase C-γ1 phosphorylation. J Immunol 186, 784-90
21149602   Curated Info

116

Kuehn HS, et al. (2011) Prostaglandin E2 activates and utilizes mTORC2 as a central signaling locus for the regulation of mast cell chemotaxis and mediator release. J Biol Chem 286, 391-402
20980255   Curated Info

117

George J, et al. (2011) Resveratrol and black tea polyphenol combination synergistically suppress mouse skin tumors growth by inhibition of activated MAPKs and p53. PLoS One 6, e23395
21887248   Curated Info

118

Huttlin EL, et al. (2010) A tissue-specific atlas of mouse protein phosphorylation and expression. Cell 143, 1174-89
21183079   Curated Info

119

Smith FD, et al. (2010) AKAP-Lbc enhances cyclic AMP control of the ERK1/2 cascade. Nat Cell Biol 12, 1242-9
21102438   Curated Info

120

Chen Y, et al. (2010) Gprc5a deletion enhances the transformed phenotype in normal and malignant lung epithelial cells by eliciting persistent Stat3 signaling induced by autocrine leukemia inhibitory factor. Cancer Res 70, 8917-26
20959490   Curated Info

121

Wu Z, et al. (2010) MAPK phosphatase-3 promotes hepatic gluconeogenesis through dephosphorylation of forkhead box O1 in mice. J Clin Invest 120, 3901-11
20921625   Curated Info

122

Matthews SA, et al. (2010) Unique functions for protein kinase D1 and protein kinase D2 in mammalian cells. Biochem J 432, 153-63
20819079   Curated Info

123

Chandrakesan P, et al. (2010) Novel changes in NF-{kappa}B activity during progression and regression phases of hyperplasia: role of MEK, ERK, and p38. J Biol Chem 285, 33485-98
20710027   Curated Info

124

Lysechko TL, Cheung SM, Ostergaard HL (2010) Regulation of the tyrosine kinase Pyk2 by calcium is through production of reactive oxygen species in cytotoxic T lymphocytes. J Biol Chem 285, 31174-84
20688918   Curated Info

125

Sanderson MP, et al. (2010) Syk and Lyn mediate distinct Syk phosphorylation events in FcɛRI-signal transduction: implications for regulation of IgE-mediated degranulation. Mol Immunol 48, 171-8
20828828   Curated Info

126

Zheng Y, et al. (2010) Protein tyrosine kinase 6 directly phosphorylates AKT and promotes AKT activation in response to epidermal growth factor. Mol Cell Biol 30, 4280-92
20606012   Curated Info

127

Faour WH, Thibodeau JF, Kennedy CR (2010) Mechanical stretch and prostaglandin E2 modulate critical signaling pathways in mouse podocytes. Cell Signal 22, 1222-30
20362052   Curated Info

128

Bartolomé A, Guillén C, Benito M (2010) Role of the TSC1-TSC2 complex in the integration of insulin and glucose signaling involved in pancreatic beta-cell proliferation. Endocrinology 151, 3084-94
20427478   Curated Info

129

Carretero J, et al. (2010) Integrative genomic and proteomic analyses identify targets for Lkb1-deficient metastatic lung tumors. Cancer Cell 17, 547-59
20541700   Curated Info

130

Iwai LK, Benoist C, Mathis D, White FM (2010) Quantitative phosphoproteomic analysis of T cell receptor signaling in diabetes prone and resistant mice. J Proteome Res 9, 3135-45
20438120   Curated Info

131

Wiśniewski JR, et al. (2010) Brain phosphoproteome obtained by a FASP-based method reveals plasma membrane protein topology. J Proteome Res 9, 3280-9
20415495   Curated Info

132

Qiao M, et al. (2010) Mst1 is an interacting protein that mediates PHLPPs' induced apoptosis. Mol Cell 38, 512-23
20513427   Curated Info

133

Lanahan AA, et al. (2010) VEGF receptor 2 endocytic trafficking regulates arterial morphogenesis. Dev Cell 18, 713-24
20434959   Curated Info

134

Morandell S, et al. (2010) QIKS--Quantitative identification of kinase substrates. Proteomics 10, 2015-25
20217869   Curated Info

135

Bonnette PC, et al. (2010) Phosphoproteomic characterization of PYK2 signaling pathways involved in osteogenesis. J Proteomics 73, 1306-20
20116462   Curated Info

136

Anastasov N, et al. (2010) C/EBPbeta expression in ALK-positive anaplastic large cell lymphomas is required for cell proliferation and is induced by the STAT3 signaling pathway. Haematologica 95, 760-7
20015877   Curated Info

137

Thien CB, et al. (2010) c-Cbl promotes T cell receptor-induced thymocyte apoptosis by activating the phosphatidylinositol 3-kinase/Akt pathway. J Biol Chem 285, 10969-81
20133944   Curated Info

138

Damdinsuren B, et al. (2010) Single round of antigen receptor signaling programs naive B cells to receive T cell help. Immunity 32, 355-66
20226693   Curated Info

139

Huang YZ, McNamara JO (2010) Mutual regulation of Src family kinases and the neurotrophin receptor TrkB. J Biol Chem 285, 8207-17
20064930   Curated Info

140

Murphy EA, et al. (2010) Disruption of angiogenesis and tumor growth with an orally active drug that stabilizes the inactive state of PDGFRbeta/B-RAF. Proc Natl Acad Sci U S A 107, 4299-304
20154271   Curated Info

141

Chuck MI, Zhu M, Shen S, Zhang W (2010) The role of the LAT-PLC-gamma1 interaction in T regulatory cell function. J Immunol 184, 2476-86
20130215   Curated Info

142

Rinschen MM, et al. (2010) Quantitative phosphoproteomic analysis reveals vasopressin V2-receptor-dependent signaling pathways in renal collecting duct cells. Proc Natl Acad Sci U S A 107, 3882-7
20139300   Curated Info

143

Zhou J (2010) CST Curation Set: 9105; Year: 2010; Biosample/Treatment: cell line, F9/untreated; Disease: testicular cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-102) Cat#: 9416
Curated Info

144

Zhou J (2010) CST Curation Set: 9104; Year: 2010; Biosample/Treatment: cell line, ES J1/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-102) Cat#: 9416
Curated Info

145

Zhou J (2010) CST Curation Set: 9109; Year: 2010; Biosample/Treatment: cell line, P19/untreated; Disease: testicular cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-102) Cat#: 9416
Curated Info

146

Zhou J (2010) CST Curation Set: 9108; Year: 2010; Biosample/Treatment: cell line, PY2/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-102) Cat#: 9416
Curated Info

147

Racaniello M, et al. (2010) Phosphorylation changes of CaMKII, ERK1/2, PKB/Akt kinases and CREB activation during early long-term potentiation at Schaffer collateral-CA1 mouse hippocampal synapses. Neurochem Res 35, 239-46
19731018   Curated Info

148

Park YK, Park H (2010) Prevention of CCAAT/enhancer-binding protein beta DNA binding by hypoxia during adipogenesis. J Biol Chem 285, 3289-99
19940121   Curated Info

149

Quoyer J, et al. (2010) GLP-1 mediates antiapoptotic effect by phosphorylating Bad through a beta-arrestin 1-mediated ERK1/2 activation in pancreatic beta-cells. J Biol Chem 285, 1989-2002
19915011   Curated Info

150

Liron T, Nahari T, Souroujon MC, Neumann D (2010) Insertion of an NPVY sequence into the cytosolic domain of the erythropoietin receptor selectively affects erythropoietin-mediated signalling and function. Biochem J 427, 305-12
20136632   Curated Info

151

Aguilar-Morante D, et al. (2010) Inhibition of glioblastoma growth by the thiadiazolidinone compound TDZD-8. PLoS One 5, e13879
21079728   Curated Info

152

Zhao L, et al. (2009) Srcasm inhibits Fyn-induced cutaneous carcinogenesis with modulation of Notch1 and p53. Cancer Res 69, 9439-47
19934324   Curated Info

153

Tucker M (2009) CST Curation Set: 8606; Year: 2009; Biosample/Treatment: cell line, embryonic stem cells (mouse)(PTEN)/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P
Curated Info

154

Tucker M (2009) CST Curation Set: 8603; Year: 2009; Biosample/Treatment: cell line, embryonic stem cells (mouse)(PTEN)/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P
Curated Info

155

Tucker M (2009) CST Curation Set: 8605; Year: 2009; Biosample/Treatment: cell line, embryonic stem cells (mouse)(PTEN)/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P
Curated Info

156

Tucker M (2009) CST Curation Set: 8607; Year: 2009; Biosample/Treatment: cell line, embryonic stem cells (mouse)(PTEN)/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P
Curated Info

157

Tucker M (2009) CST Curation Set: 8602; Year: 2009; Biosample/Treatment: cell line, embryonic stem cells (mouse)(PTEN)/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P
Curated Info

158

Tucker M (2009) CST Curation Set: 8561; Year: 2009; Biosample/Treatment: cell line, embryonic stem cells (mouse)(PTEN)/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS*/T*) Immunoaffinity Beads Cat#: 1978
Curated Info

159

Tucker M (2009) CST Curation Set: 8559; Year: 2009; Biosample/Treatment: cell line, embryonic stem cells (mouse)(PTEN)/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS*/T*) Immunoaffinity Beads Cat#: 1978
Curated Info

160

Tucker M (2009) CST Curation Set: 8562; Year: 2009; Biosample/Treatment: cell line, embryonic stem cells (mouse)(PTEN)/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS*/T*) Immunoaffinity Beads Cat#: 1978
Curated Info

161

Tucker M (2009) CST Curation Set: 8560; Year: 2009; Biosample/Treatment: cell line, embryonic stem cells (mouse)(PTEN)/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST]
Curated Info

162

Tucker M (2009) CST Curation Set: 8555; Year: 2009; Biosample/Treatment: cell line, embryonic stem cells (mouse)(PTEN)/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS*/T*) Immunoaffinity Beads Cat#: 1978
Curated Info

163

Tucker M (2009) CST Curation Set: 8557; Year: 2009; Biosample/Treatment: cell line, embryonic stem cells (mouse)(PTEN)/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS*/T*) Immunoaffinity Beads Cat#: 1978
Curated Info

164

Tucker M (2009) CST Curation Set: 8558; Year: 2009; Biosample/Treatment: cell line, embryonic stem cells (mouse)(PTEN)/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS*/T*) Immunoaffinity Beads Cat#: 1978
Curated Info

165

Tucker M (2009) CST Curation Set: 8556; Year: 2009; Biosample/Treatment: cell line, embryonic stem cells (mouse)(PTEN)/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS*/T*) Immunoaffinity Beads Cat#: 1978
Curated Info

166

Salmond RJ, Emery J, Okkenhaug K, Zamoyska R (2009) MAPK, phosphatidylinositol 3-kinase, and mammalian target of rapamycin pathways converge at the level of ribosomal protein S6 phosphorylation to control metabolic signaling in CD8 T cells. J Immunol 183, 7388-97
19917692   Curated Info

167

Browne CD, et al. (2009) Suppression of phosphatidylinositol 3,4,5-trisphosphate production is a key determinant of B cell anergy. Immunity 31, 749-60
19896393   Curated Info

168

Tucker M (2009) CST Curation Set: 8089; Year: 2009; Biosample/Treatment: cell line, embryonic stem cells (mouse)(PTEN)/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

169

Tucker M (2009) CST Curation Set: 8084; Year: 2009; Biosample/Treatment: cell line, embryonic stem cells (mouse)(PTEN)/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

170

Tucker M (2009) CST Curation Set: 8081; Year: 2009; Biosample/Treatment: cell line, embryonic stem cells (mouse)(PTEN)/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

171

Tucker M (2009) CST Curation Set: 8088; Year: 2009; Biosample/Treatment: cell line, embryonic stem cells (mouse)(PTEN)/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

172

Tucker M (2009) CST Curation Set: 8077; Year: 2009; Biosample/Treatment: cell line, embryonic stem cells (mouse)(PTEN)/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine (P-Tyr-1000) Rabbit mAb Cat#: 8954, Phospho-Tyrosine Rabbit mAb (p-Tyr-1000) Immunoaffinity Beads Cat#: 8876
Curated Info

173

Tucker M (2009) CST Curation Set: 8085; Year: 2009; Biosample/Treatment: cell line, embryonic stem cells (mouse)(PTEN)/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

174

Tucker M (2009) CST Curation Set: 8080; Year: 2009; Biosample/Treatment: cell line, embryonic stem cells (mouse)(PTEN)/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

175

Tucker M (2009) CST Curation Set: 8072; Year: 2009; Biosample/Treatment: cell line, embryonic stem cells (mouse)(PTEN)/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine (P-Tyr-1000) Rabbit mAb Cat#: 8954, Phospho-Tyrosine Rabbit mAb (p-Tyr-1000) Immunoaffinity Beads Cat#: 8876
Curated Info

176

Choudhary C, et al. (2009) Mislocalized activation of oncogenic RTKs switches downstream signaling outcomes. Mol Cell 36, 326-39
19854140   Curated Info

177

Guo A (2009) CST Curation Set: 8168; Year: 2009; Biosample/Treatment: tissue, testis/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: (F/Y/M)Xp[ST](L/I/M)
Curated Info

178

Guo A (2009) CST Curation Set: 8170; Year: 2009; Biosample/Treatment: tissue, thymus/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: (F/Y/M)Xp[ST](L/I/M)
Curated Info

179

Guo A (2009) CST Curation Set: 8167; Year: 2009; Biosample/Treatment: tissue, testis/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: (F/Y/M)Xp[ST](L/I/M)
Curated Info

180

McPherson VA, et al. (2009) SH2 domain-containing phosphatase-2 protein-tyrosine phosphatase promotes Fc(epsilon)RI-induced activation of Fyn and Erk pathways leading to TNF(alpha) release from bone marrow-derived mast cells. J Immunol 183, 4940-7
19786542   Curated Info

181

Santamaría E, et al. (2009) Regulation of stathmin phosphorylation in mouse liver progenitor-29 cells during proteasome inhibition. Proteomics 9, 4495-506
19688729   Curated Info

182

Guo A (2009) CST Curation Set: 7710; Year: 2009; Biosample/Treatment: tissue, thymus/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

183

Guo A (2009) CST Curation Set: 7709; Year: 2009; Biosample/Treatment: tissue, testis/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

184

Guo A (2009) CST Curation Set: 7708; Year: 2009; Biosample/Treatment: tissue, spleen/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

185

Joshi S, et al. (2009) Type I interferon (IFN)-dependent activation of Mnk1 and its role in the generation of growth inhibitory responses. Proc Natl Acad Sci U S A 106, 12097-102
19574459   Curated Info

186

Zhou J (2009) CST Curation Set: 7383; Year: 2009; Biosample/Treatment: tissue, brain/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: QXp[ST]
Curated Info

187

Zhou J (2009) CST Curation Set: 7375; Year: 2009; Biosample/Treatment: tissue, brain/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: YXp[ST]
Curated Info

188

Zhou J (2009) CST Curation Set: 7376; Year: 2009; Biosample/Treatment: tissue, brain/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: YXp[ST]
Curated Info

189

Moritz A (2009) CST Curation Set: 7223; Year: 2009; Biosample/Treatment: cell line, BaF3/serum starved; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

190

Possemato A (2009) CST Curation Set: 7168; Year: 2009; Biosample/Treatment: cell line, RAW 264.7/LPS; Disease: leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

191

Possemato A (2009) CST Curation Set: 7169; Year: 2009; Biosample/Treatment: cell line, RAW 264.7/MG132; Disease: leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

192

Possemato A (2009) CST Curation Set: 7167; Year: 2009; Biosample/Treatment: cell line, RAW 264.7/LPS; Disease: leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

193

Possemato A (2009) CST Curation Set: 7166; Year: 2009; Biosample/Treatment: cell line, RAW 264.7/control; Disease: leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

194

Sinnett-Smith J, et al. (2009) Protein Kinase D Mediates Mitogenic Signaling by Gq-coupled Receptors through Protein Kinase C-independent Regulation of Activation Loop Ser744 and Ser748 Phosphorylation. J Biol Chem 284, 13434-45
19289471   Curated Info

195

Guo A (2009) CST Curation Set: 6839; Year: 2009; Biosample/Treatment: cell line, mouse lung fibroblasts/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS*/T*) (23C8D2) Rabbit mAb Cat#: 10001, PTMScan(R) Phospho-Akt Substrate Motif (RXRXXS*/T*) Immunoaffinity Beads Cat#: 1979
Curated Info

196

Lee DH, et al. (2009) Targeted disruption of ROCK1 causes insulin resistance in vivo. J Biol Chem 284, 11776-80
19276091   Curated Info

197

Chung BM, et al. (2009) The role of cooperativity with Src in oncogenic transformation mediated by non-small cell lung cancer-associated EGF receptor mutants. Oncogene 28, 1821-32
19305428   Curated Info

198

Tucker DE, et al. (2009) Role of Phosphorylation and Basic Residues in the Catalytic Domain of Cytosolic Phospholipase A2{alpha} in Regulating Interfacial Kinetics and Binding and Cellular Function. J Biol Chem 284, 9596-611
19176526   Curated Info

199

Furusawa J, et al. (2009) Glycyrrhiza inflata-derived chalcones, Licochalcone A, Licochalcone B and Licochalcone D, inhibit phosphorylation of NF-kappaB p65 in LPS signaling pathway. Int Immunopharmacol 9, 499-507
19291859   Curated Info

200

Li Y (2009) CST Curation Set: 6302; Year: 2009; Biosample/Treatment: cell line, MEDF Ras V12 HDAC6-/+/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

201

Li Y (2009) CST Curation Set: 6303; Year: 2009; Biosample/Treatment: cell line, MEDF Ras V12 HDAC6-/+/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

202

Li Y (2009) CST Curation Set: 6297; Year: 2009; Biosample/Treatment: cell line, MEF/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

203

Li Y (2009) CST Curation Set: 6298; Year: 2009; Biosample/Treatment: cell line, MEF Ras v12/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

204

Li Y (2009) CST Curation Set: 6299; Year: 2009; Biosample/Treatment: cell line, MEF Ras v12/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

205

Li Y (2009) CST Curation Set: 6296; Year: 2009; Biosample/Treatment: cell line, MEF/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

206

Catalanotti F, et al. (2009) A Mek1-Mek2 heterodimer determines the strength and duration of the Erk signal. Nat Struct Mol Biol 16, 294-303
19219045   Curated Info

207

Olson LE, Soriano P (2009) Increased PDGFRalpha activation disrupts connective tissue development and drives systemic fibrosis. Dev Cell 16, 303-13
19217431   Curated Info

208

Das M, et al. (2009) Induction of hepatitis by JNK-mediated expression of TNF-alpha. Cell 136, 249-60
19167327   Curated Info

209

van Gorp AG, et al. (2009) AGC kinases regulate phosphorylation and activation of eukaryotic translation initiation factor 4B. Oncogene 28, 95-106
18836482   Curated Info

210

Tallent MK, et al. (2009) In vivo modulation of O-GlcNAc levels regulates hippocampal synaptic plasticity through interplay with phosphorylation. J Biol Chem 284, 174-81
19004831   Curated Info

211

McPherson VA, et al. (2009) Contributions of F-BAR and SH2 domains of Fes protein tyrosine kinase for coupling to the FcepsilonRI pathway in mast cells. Mol Cell Biol 29, 389-401
19001085   Curated Info

212

Lorenz K, Schmitt JP, Schmitteckert EM, Lohse MJ (2009) A new type of ERK1/2 autophosphorylation causes cardiac hypertrophy. Nat Med 15, 75-83
19060905   Curated Info

213

Conche C, Boulla G, Trautmann A, Randriamampita C (2009) T cell adhesion primes antigen receptor-induced calcium responses through a transient rise in adenosine 3',5'-cyclic monophosphate. Immunity 30, 33-43
19144315   Curated Info

214

Zanivan S, et al. (2008) Solid tumor proteome and phosphoproteome analysis by high resolution mass spectrometry. J Proteome Res 7, 5314-26
19367708   Curated Info

215

Stokes M (2008) CST Curation Set: 5664; Year: 2008; Biosample/Treatment: tissue, heart/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

216

Stokes M (2008) CST Curation Set: 5665; Year: 2008; Biosample/Treatment: tissue, heart/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

217

Stokes M (2008) CST Curation Set: 5666; Year: 2008; Biosample/Treatment: cell line, Noonan Syndrome mouse heart/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

218

Stokes M (2008) CST Curation Set: 5667; Year: 2008; Biosample/Treatment: cell line, Noonan Syndrome mouse heart/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

219

Simon C, et al. (2008) Lnk adaptor protein down-regulates specific Kit-induced signaling pathways in primary mast cells. Blood 112, 4039-47
18753636   Curated Info

220

Kaneda T, et al. (2008) Mutation of Y925F in focal adhesion kinase (FAK) suppresses melanoma cell proliferation and metastasis. Cancer Lett 270, 354-61
18606490   Curated Info

221

Pan C, Gnad F, Olsen JV, Mann M (2008) Quantitative phosphoproteome analysis of a mouse liver cell line reveals specificity of phosphatase inhibitors. Proteomics 8, 4534-46
18846507   Curated Info

222

Mariappan MM, et al. (2008) Glycogen synthase kinase 3beta is a novel regulator of high glucose- and high insulin-induced extracellular matrix protein synthesis in renal proximal tubular epithelial cells. J Biol Chem 283, 30566-75
18701453   Curated Info

223

Bécart S, et al. (2008) Tyrosine-phosphorylation-dependent translocation of the SLAT protein to the immunological synapse is required for NFAT transcription factor activation. Immunity 29, 704-19
18976935   Curated Info

224

Samayawardhena LA, Pallen CJ (2008) Protein-tyrosine phosphatase alpha regulates stem cell factor-dependent c-Kit activation and migration of mast cells. J Biol Chem 283, 29175-85
18725415   Curated Info

225

Nishi A, et al. (2008) Distinct roles of PDE4 and PDE10A in the regulation of cAMP/PKA signaling in the striatum. J Neurosci 28, 10460-71
18923023   Curated Info

226

Partovian C, et al. (2008) Syndecan-4 regulates subcellular localization of mTOR Complex2 and Akt activation in a PKCalpha-dependent manner in endothelial cells. Mol Cell 32, 140-9
18851840   Curated Info

227

Rikova K (2008) CST Curation Set: 5292; Year: 2008; Biosample/Treatment: cell line, Dana Farber-S2/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]Q
Curated Info

228

Rikova K (2008) CST Curation Set: 5293; Year: 2008; Biosample/Treatment: cell line, Dana Farber-S3/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]Q
Curated Info

229

Rikova K (2008) CST Curation Set: 5294; Year: 2008; Biosample/Treatment: cell line, Dana Farber-KTL-1/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]Q
Curated Info

230

Rikova K (2008) CST Curation Set: 5295; Year: 2008; Biosample/Treatment: cell line, Dana Farber-KTL-3/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]Q
Curated Info

231

Rikova K (2008) CST Curation Set: 5296; Year: 2008; Biosample/Treatment: cell line, Dana Farber-KTL(LN)-4/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]Q
Curated Info

232

Rikova K (2008) CST Curation Set: 5297; Year: 2008; Biosample/Treatment: cell line, Dana Farber-KTL(LN)-5/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]Q
Curated Info

233

Mertins P, et al. (2008) Investigation of protein-tyrosine phosphatase 1B function by quantitative proteomics. Mol Cell Proteomics 7, 1763-77
18515860   Curated Info

234

Noble C, et al. (2008) CRAF autophosphorylation of serine 621 is required to prevent its proteasome-mediated degradation. Mol Cell 31, 862-72
18922468   Curated Info

235

Encinas M, et al. (2008) Analysis of Ret knockin mice reveals a critical role for IKKs, but not PI 3-K, in neurotrophic factor-induced survival of sympathetic neurons. Cell Death Differ 15, 1510-21
18497757   Curated Info

236

Possemato A (2008) CST Curation Set: 5027; Year: 2008; Biosample/Treatment: cell line, C2C12/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS*/T*) Immunoaffinity Beads Cat#: 1978
Curated Info

237

Possemato A (2008) CST Curation Set: 5028; Year: 2008; Biosample/Treatment: cell line, C2C12/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS*/T*) Immunoaffinity Beads Cat#: 1978
Curated Info

238

Hermann-Kleiter N, et al. (2008) The nuclear orphan receptor NR2F6 suppresses lymphocyte activation and T helper 17-dependent autoimmunity. Immunity 29, 205-16
18701084   Curated Info

239

Rikova K (2008) CST Curation Set: 4985; Year: 2008; Biosample/Treatment: tissue, lung/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

240

Tchivilev I, et al. (2008) Identification of a protective role for protein phosphatase 1cgamma1 against oxidative stress-induced vascular smooth muscle cell apoptosis. J Biol Chem 283, 22193-205
18540044   Curated Info

241

Possemato A (2008) CST Curation Set: 4930; Year: 2008; Biosample/Treatment: cell line, C2C12/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

242

Possemato A (2008) CST Curation Set: 4931; Year: 2008; Biosample/Treatment: cell line, C2C12/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

243

Possemato A (2008) CST Curation Set: 4932; Year: 2008; Biosample/Treatment: cell line, C2C12/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

244

Possemato A (2008) CST Curation Set: 4933; Year: 2008; Biosample/Treatment: cell line, C2C12/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

245

Possemato A (2008) CST Curation Set: 4934; Year: 2008; Biosample/Treatment: cell line, C2C12/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

246

Possemato A (2008) CST Curation Set: 4935; Year: 2008; Biosample/Treatment: cell line, C2C12/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

247

Possemato A (2008) CST Curation Set: 4936; Year: 2008; Biosample/Treatment: cell line, C2C12/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

248

Possemato A (2008) CST Curation Set: 4929; Year: 2008; Biosample/Treatment: cell line, C2C12/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

249

Luo W, et al. (2008) Global impact of oncogenic Src on a phosphotyrosine proteome. J Proteome Res 7, 3447-60
18563927   Curated Info

250

Stokes M (2008) CST Curation Set: 4845; Year: 2008; Biosample/Treatment: tissue, heart/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

251

Stokes M (2008) CST Curation Set: 4846; Year: 2008; Biosample/Treatment: tissue, heart/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

252

Stokes M (2008) CST Curation Set: 4847; Year: 2008; Biosample/Treatment: tissue, heart/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

253

Rikova K (2008) CST Curation Set: 4790; Year: 2008; Biosample/Treatment: cell line, Dana Farber-KT-1/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

254

Rikova K (2008) CST Curation Set: 4775; Year: 2008; Biosample/Treatment: cell line, Dana Farber-KTL(LN)-4/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

255

Rikova K (2008) CST Curation Set: 4788; Year: 2008; Biosample/Treatment: cell line, Dana Farber-KTL(LN)-5/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

256

Rikova K (2008) CST Curation Set: 4769; Year: 2008; Biosample/Treatment: cell line, Dana Farber-S3/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

257

Rikova K (2008) CST Curation Set: 4771; Year: 2008; Biosample/Treatment: cell line, Dana Farber-KTL-1/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

258

Rikova K (2008) CST Curation Set: 4839; Year: 2008; Biosample/Treatment: cell line, Dana Farber-S1/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

259

Rikova K (2008) CST Curation Set: 4840; Year: 2008; Biosample/Treatment: cell line, Dana Farber-S2/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

260

Rikova K (2008) CST Curation Set: 4837; Year: 2008; Biosample/Treatment: cell line, Dana Farber-L1/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

261

Rikova K (2008) CST Curation Set: 4838; Year: 2008; Biosample/Treatment: cell line, Dana Farber-L2/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

262

Rikova K (2008) CST Curation Set: 4763; Year: 2008; Biosample/Treatment: cell line, Dana Farber-S1/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

263

Rikova K (2008) CST Curation Set: 4765; Year: 2008; Biosample/Treatment: cell line, Dana Farber-S2/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

264

Cha HC, et al. (2008) Phosphorylation of CCAAT/enhancer-binding protein alpha regulates GLUT4 expression and glucose transport in adipocytes. J Biol Chem 283, 18002-11
18408001   Curated Info

265

Li Y (2008) CST Curation Set: 4544; Year: 2008; Biosample/Treatment: cell line, 10T1/2/FGF; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

266

Li Y (2008) CST Curation Set: 4543; Year: 2008; Biosample/Treatment: cell line, 10T1/2/FGF; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

267

Li Y (2008) CST Curation Set: 4542; Year: 2008; Biosample/Treatment: cell line, 10T1/2/FGF; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

268

Li Y (2008) CST Curation Set: 4541; Year: 2008; Biosample/Treatment: cell line, 10T1/2/control; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

269

Rikova K (2008) CST Curation Set: 4476; Year: 2008; Biosample/Treatment: cell line, MD Ander 1158(393P)/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

270

Rikova K (2008) CST Curation Set: 4481; Year: 2008; Biosample/Treatment: cell line, MD Ander a0859/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

271

Oneyama C, et al. (2008) The lipid raft-anchored adaptor protein Cbp controls the oncogenic potential of c-Src. Mol Cell 30, 426-36
18498747   Curated Info

272

Rikova K (2008) CST Curation Set: 4477; Year: 2008; Biosample/Treatment: cell line, MD Ander 1154/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

273

Rikova K (2008) CST Curation Set: 4478; Year: 2008; Biosample/Treatment: cell line, MD Ander 0895/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

274

Rikova K (2008) CST Curation Set: 4479; Year: 2008; Biosample/Treatment: cell line, MD Ander 1202(344SQ)/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

275

Rikova K (2008) CST Curation Set: 4480; Year: 2008; Biosample/Treatment: cell line, MD Ander 1249/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

276

Rikova K (2008) CST Curation Set: 4474; Year: 2008; Biosample/Treatment: cell line, MD Ander 393LN/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

277

Rikova K (2008) CST Curation Set: 4475; Year: 2008; Biosample/Treatment: cell line, MD Ander 1169/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

278

Rikova K (2008) CST Curation Set: 4464; Year: 2008; Biosample/Treatment: tissue, lung/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS*/T*) Immunoaffinity Beads Cat#: 1978
Curated Info

279

Rikova K (2008) CST Curation Set: 4437; Year: 2008; Biosample/Treatment: tissue, lung/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

280

Rikova K (2008) CST Curation Set: 4438; Year: 2008; Biosample/Treatment: tissue, lung/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

281

Rikova K (2008) CST Curation Set: 4439; Year: 2008; Biosample/Treatment: tissue, lung/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

282

Rikova K (2008) CST Curation Set: 4440; Year: 2008; Biosample/Treatment: tissue, lung/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

283

Bayascas JR, et al. (2008) Mutation of the PDK1 PH domain inhibits protein kinase B/Akt, leading to small size and insulin resistance. Mol Cell Biol 28, 3258-72
18347057   Curated Info

284

Ren H (2008) CST Curation Set: 4335; Year: 2008; Biosample/Treatment: cell line, EGFR_WT/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

285

Ren H (2008) CST Curation Set: 4336; Year: 2008; Biosample/Treatment: cell line, EGFR_M/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

286

Ren H (2008) CST Curation Set: 4337; Year: 2008; Biosample/Treatment: cell line, Ras_WT/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

287

Zhou J (2008) CST Curation Set: 4322; Year: 2008; Biosample/Treatment: tissue, brain/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY
Curated Info

288

Zhou J (2008) CST Curation Set: 4323; Year: 2008; Biosample/Treatment: tissue, brain/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY
Curated Info

289

Zhou J (2008) CST Curation Set: 4325; Year: 2008; Biosample/Treatment: tissue, liver/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY
Curated Info

290

Yasuda T, et al. (2008) Erk kinases link pre-B cell receptor signaling to transcriptional events required for early B cell expansion. Immunity 28, 499-508
18356083   Curated Info

291

Wernig G, et al. (2008) Efficacy of TG101348, a selective JAK2 inhibitor, in treatment of a murine model of JAK2V617F-induced polycythemia vera. Cancer Cell 13, 311-20
18394554   Curated Info

292

Rikova K (2008) CST Curation Set: 4249; Year: 2008; Biosample/Treatment: tissue, lung/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

293

Rikova K (2008) CST Curation Set: 4250; Year: 2008; Biosample/Treatment: tissue, lung/Tarceva; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

294

Rikova K (2008) CST Curation Set: 4251; Year: 2008; Biosample/Treatment: tissue, lung/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

295

Rikova K (2008) CST Curation Set: 4252; Year: 2008; Biosample/Treatment: tissue, lung/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

296

Rikova K (2008) CST Curation Set: 4253; Year: 2008; Biosample/Treatment: tissue, lung/Tarceva; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

297

Rikova K (2008) CST Curation Set: 4254; Year: 2008; Biosample/Treatment: tissue, lung/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

298

Bakker W, et al. (2008) Protein kinase C theta activation induces insulin-mediated constriction of muscle resistance arteries. Diabetes 57, 706-13
18086904   Curated Info

299

Samarakoon R, Higgins SP, Higgins CE, Higgins PJ (2008) TGF-beta1-induced plasminogen activator inhibitor-1 expression in vascular smooth muscle cells requires pp60(c-src)/EGFR(Y845) and Rho/ROCK signaling. J Mol Cell Cardiol 44, 527-38
18255094   Curated Info

300

Krüger M, et al. (2008) Dissection of the insulin signaling pathway via quantitative phosphoproteomics. Proc Natl Acad Sci U S A 105, 2451-6
18268350   Curated Info

301

Alejandro EU, Johnson JD (2008) Inhibition of Raf-1 alters multiple downstream pathways to induce pancreatic beta-cell apoptosis. J Biol Chem 283, 2407-17
18006502   Curated Info

302

Takatori A, et al. (2008) Differential transmission of MEKK1 morphogenetic signals by JNK1 and JNK2. Development 135, 23-32
18032450   Curated Info

303

Ballif BA, Carey GR, Sunyaev SR, Gygi SP (2008) Large-scale identification and evolution indexing of tyrosine phosphorylation sites from murine brain. J Proteome Res 7, 311-8
18034455   Curated Info

304

Tyagi A, et al. (2007) Chemopreventive effects of silymarin and silibinin on N-butyl-N-(4-hydroxybutyl) nitrosamine induced urinary bladder carcinogenesis in male ICR mice. Mol Cancer Ther 6, 3248-55
18089718   Curated Info

305

Hu HJ, et al. (2007) Metabotropic glutamate receptor 5 modulates nociceptive plasticity via extracellular signal-regulated kinase-Kv4.2 signaling in spinal cord dorsal horn neurons. J Neurosci 27, 13181-91
18045912   Curated Info

306

Cao L, et al. (2007) Quantitative time-resolved phosphoproteomic analysis of mast cell signaling. J Immunol 179, 5864-76
17947660   Curated Info

307

Gu T (2007) CST Curation Set: 3402; Year: 2007; Biosample/Treatment: cell line, Baf3(MSCV-NEO)/IL3 withdrawal; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

308

Gu T (2007) CST Curation Set: 3403; Year: 2007; Biosample/Treatment: cell line, Baf3(MSCV-NEO)/IL3 withdrawal; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

309

Gu T (2007) CST Curation Set: 3404; Year: 2007; Biosample/Treatment: cell line, Baf3(MSCV-NEO-FLT3/ITD)/IL3 withdrawal; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

310

Gu T (2007) CST Curation Set: 3405; Year: 2007; Biosample/Treatment: cell line, Baf3(MSCV-NEO-FLT3/ITD)/IL3 withdrawal; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

311

Gu T (2007) CST Curation Set: 3406; Year: 2007; Biosample/Treatment: cell line, Baf3(PLXSN-NEO-FLT3/ITD)/IL3 withdrawal; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

312

Gu T (2007) CST Curation Set: 3407; Year: 2007; Biosample/Treatment: cell line, Baf3(PLXSN-NEO-FLT3/ITD)/IL3 withdrawal; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

313

Gu T (2007) CST Curation Set: 3408; Year: 2007; Biosample/Treatment: cell line, Baf3(PLXSN-NEO-FLT3 (D835Y))/IL3 withdrawal; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

314

Gu T (2007) CST Curation Set: 3409; Year: 2007; Biosample/Treatment: cell line, Baf3(PLXSN-NEO-FLT3 (D835Y))/IL3 withdrawal; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

315

Schenning M, van Tiel CM, Wirtz KW, Snoek GT (2007) The anti-apoptotic MAP kinase pathway is inhibited in NIH3T3 fibroblasts with increased expression of phosphatidylinositol transfer protein beta. Biochim Biophys Acta 1773, 1664-71
17683809   Curated Info

316

Robinson MJ, et al. (2007) Phosphorylation of TPL-2 on serine 400 is essential for lipopolysaccharide activation of extracellular signal-regulated kinase in macrophages. Mol Cell Biol 27, 7355-64
17709378   Curated Info

317

Le Y, et al. (2007) SOCS3 protein developmentally regulates the chemokine receptor CXCR4-FAK signaling pathway during B lymphopoiesis. Immunity 27, 811-23
18031698   Curated Info

318

Zaru R, et al. (2007) The MAPK-activated kinase Rsk controls an acute Toll-like receptor signaling response in dendritic cells and is activated through two distinct pathways. Nat Immunol 8, 1227-35
17906627   Curated Info

319

Yu J (2007) CST Curation Set: 3379; Year: 2007; Biosample/Treatment: cell line, Mouse Mesenchymal Stem Cells/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

320

Yu J (2007) CST Curation Set: 3380; Year: 2007; Biosample/Treatment: cell line, Mouse Mesenchymal Stem Cells/bFGF; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

321

Yamanaka A, et al. (2007) Involvement of CaM kinase II in gonadotropin-releasing hormone-induced activation of MAP kinase in cultured hypothalamic neurons. Arch Biochem Biophys 466, 234-41
17706588   Curated Info

322

Cho YY, et al. (2007) Ribosomal S6 kinase 2 is a key regulator in tumor promoter induced cell transformation. Cancer Res 67, 8104-12
17804722   Curated Info

323

Falin RA, Cotton CU (2007) Acute downregulation of ENaC by EGF involves the PY motif and putative ERK phosphorylation site. J Gen Physiol 130, 313-28
17724164   Curated Info

324

McNeill L, et al. (2007) The differential regulation of Lck kinase phosphorylation sites by CD45 is critical for T cell receptor signaling responses. Immunity 27, 425-37
17719247   Curated Info

325

Merla R, et al. (2007) The central role of adenosine in statin-induced ERK1/2, Akt, and eNOS phosphorylation. Am J Physiol Heart Circ Physiol 293, H1918-28
17616749   Curated Info

326

Jaeschke A, Davis RJ (2007) Metabolic stress signaling mediated by mixed-lineage kinases. Mol Cell 27, 498-508
17679097   Curated Info

327

Xuan YT, et al. (2007) Endothelial nitric oxide synthase plays an obligatory role in the late phase of ischemic preconditioning by activating the protein kinase C epsilon p44/42 mitogen-activated protein kinase pSer-signal transducers and activators of transcription1/3 pathway. Circulation 116, 535-44
17606840   Curated Info

328

Li X, et al. (2007) Role of cdk2 in the sequential phosphorylation/activation of C/EBPbeta during adipocyte differentiation. Proc Natl Acad Sci U S A 104, 11597-602
17601773   Curated Info

329

Dong S, et al. (2007) 14-3-3 Integrates prosurvival signals mediated by the AKT and MAPK pathways in ZNF198-FGFR1-transformed hematopoietic cells. Blood 110, 360-9
17389761   Curated Info

330

Yoshizaki T, et al. (2007) Myosin 5a is an insulin-stimulated Akt2 (protein kinase Bbeta) substrate modulating GLUT4 vesicle translocation. Mol Cell Biol 27, 5172-83
17515613   Curated Info

331

Takeshita S, et al. (2007) c-Fms tyrosine 559 is a major mediator of M-CSF-induced proliferation of primary macrophages. J Biol Chem 282, 18980-90
17420255   Curated Info